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“To those who crossed oceans for the hope of a decent life, 
maybe one day you won’t be seen as a burden anymore, 








POPULAR SCIENCE SUMMARY OF THE THESIS 
Tuberculosis (TB) is an infectious disease that most commonly affects the lungs. In Sweden, 
the vast majority of TB cases are among migrants who have acquired TB infection in their 
home country or during the migration process. They may carry a dormant form of TB, so-
called latent tuberculosis infection (LTBI), which can later activate to infectious TB disease. 
This activation can be hindered through screening and treatment of LTBI. Therefore, one of 
the key interventions to control TB in Sweden is screening and treating LTBI. Newly arrived 
migrants are offered a health examination where they get tested for infectious diseases 
including TB and LTBI. Following a positive LTBI test, individuals can be referred to a TB 
clinic for follow-up and potential prescription of LTBI treatment.  
This thesis is composed of 5 articles that explore the experiences of newly arrived migrants 
with the health examination, LTBI/TB diagnosis and treatment and assess the cost 
effectiveness of the LTBI screening strategy in Stockholm Region.  
As the overall aim of the thesis was to assess the cost effectiveness of LTBI screening, Study 
I was a literature review that looked at the methodology of economic modelling in this field 
and developed an analytical framework, setting the stage to perform the cost-effectiveness 
analysis in Study V. The economic modelling study showed that screening was cost effective 
among individuals in the age group 13 to 19, while it was less cost effective among younger 
children mainly because LTBI was not prevalent in this group. For the age group 20 to 34, 
screening was also less cost effective compared to the adolescent group because patients, 
even when screened positive for LTBI, were rarely referred to the TB clinic to start treatment. 
However, if more patients would start treatment, screening is expected to be cost effective in 
this age group too. Finally, screening was not cost effective for people above the age of 34. 
Study II explored the experiences of newly arrived migrants with health examination through 
conducting interviews with them. The interviewed migrants expressed positive attitude 
toward the health examination but perceived the examination as too much focused on 
infectious disease control rather than an examination that focuses on all their health needs. In 
addition, they expressed a need for better information about the Swedish healthcare system 
during the examination. 
Study III and IV relied on interviews and surveys that included instrument to measure the 
health-related quality of life of patients. The results showed that TB patients are affected in 
terms of physical and mental health. While LTBI patients did not have a compromised 
quality of life, there was a large proportion of them who reported mental health concerns, 
although these concerns can be related to their asylum-seeking process. Nevertheless, several 
expressed fear of infecting others and about the burden of TB on them. Therefore, addressing 
fears and misinformation through counseling might be beneficial in this group. 
Altogether, these results emphasize the need for a better communication system between 
migrants and healthcare professionals to address concerns and fears during health 
examination, LTBI /TB diagnosis and treatment. Due to ethical and economic reasons, LTBI 








Introduction The burden of tuberculosis (TB) in Sweden is concentrated among migrants 
from high TB incidence countries. The incident cases in Sweden arise mainly through 
reactivation of a latent tuberculosis infection (LTBI) acquired in the home country or during 
transit. Progression from LTBI to active TB disease can be prevented through treatment with 
anti-tubercular medicines. LTBI screening is therefore offered for asylum seekers and 
refugees in Sweden as part of a voluntary health examination (HE). Little is known about 
their experiences of LTBI screening and treatment. In addition, there has been no previous 
evaluation of the cost-effectiveness of the current LTBI screening policy in Stockholm or 
Sweden. 
Aims The overarching aim of this thesis was to determine the cost-effectiveness of the 
current strategy of screening for LTBI among asylum seekers in Stockholm. This aim was 
achieved through the following specific objectives: 1) to assess the methodology of 
previously published economic models of LTBI screening and to develop an analytical 
framework, 2) to understand the experiences of asylum seekers with HE, 3) to quantify 
health-related quality of life (HRQoL) of LTBI patients and to explore the factors influencing 
it, 4) to quantify the HRQoL of TB patients, and 5) to assess the cost effectiveness of LTBI 
screening through an economic model. 
Methods A qualitative study was designed to explore the experiences of asylum seekers with 
HE; semi-structured interviews were conducted based on an interview guide. For the HRQoL 
studies, a HRQoL instrument, EQ-5D, and a mental health screening instrument, RHS-15, 
were used. For the LTBI patients, a mixed-method design was used, in which a cross-
sectional survey using the EQ-5D and RHS-15 instruments was combined with qualitative 
interviews of a subgroup. For the TB patients, a longitudinal study design was used in which 
a cohort filled the EQ-5D instrument at the beginning and the end of treatment. A literature 
review was performed to assess the methodology of published economic modelling studies of 
LTBI screening. Through this review a framework was developed guiding the development 
of an economic model (a Markov model) to assess the cost effectiveness of the current LTBI 
screening in Stockholm compared to a hypothetical scenario of no screening. The analysis 
adopted the societal perspective, and results were presented in term of incremental cost-
effectiveness ratios (ICERs); taking 500 000 SEK/QALY as a cost-effectiveness threshold.  
Results The HE was perceived as available by asylum seekers, with no serious physical or 
financial accessibility problems. They felt respected and trusted by the healthcare workers. 
However, information about the Swedish healthcare system was perceived to be incomplete 
and the HE was seen as non-responsive to their individual needs with main focus on 
infectious diseases. Among LTBI patients, 38% screened positive for mental health concerns 
using RHS-15, and 28% scored problems on mental health dimension of EQ-5D. These 
patients expressed fear of being contagious to others, an ambiguous threat of a vague 
diagnosis and future uncertainties about developing TB disease. However, LTBI patients had 
no overall HRQoL decrement. TB patients had a HRQoL utility score of 0,72 at the 
beginning of treatment, which improved significantly by the end of the treatment to 0,84. The 
cost effectiveness results showed that ICER is the lowest among the age group 13 to 19 at 
303 881 SEK/QALY, which was the only ICER below the 500 000 SEK/QALY threshold. 
 
 
Discussion Asylum seekers had a generally positive attitude towards HE, including TB and 
LTBI screening, but also emphasized the need to broaden the focus on all health needs rather 
than solely focusing on infectious diseases. LTBI patients might have a compromised mental 
health partly linked to fear of TB disease. Therefore, it can be beneficial to address these 
concerns as part of LTBI management. TB patients had a compromised HRQoL and a 
decrement of 0,28 for TB patients is recommended to be used in economic evaluations. LTBI 
screening among asylum seekers in Stockholm is cost effective in the age group 13 to 19 
while it is moderately cost-effective in the age groups 0 to 12 and 20 to 34 years. The latter is 
mainly due to the restrictive practices of offering treatment for persons over the age of 20 
years. 
Conclusions Health examination is an acceptable, accessible health service. However, its 
quality can be improved by broadening the focus beyond infectious disease control. An LTBI 
diagnosis can be misunderstood as active TB and linked to stigma. The cost-effectiveness 
analysis showed that screening is cost effective only when preventive treatment is offered. 
Therefore, due to ethical and economic reasons, LTBI screening should only be performed 
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1.1 TUBERCULOSIS DISEASE 
1.1.1 Pathogenesis 
Tuberculosis (TB) is an ancient bacterial disease that has affected humans for thousands of 
years. It is caused by Mycobacterium tuberculosis (M. tuberculosis), a bacillus that was 
discovered by Dr. Robert Koch in 1882. (1) TB is an airborne communicable disease that can 
be transmitted by aerosols droplets through coughing, talking or sneezing. Many factors 
influence the probability of transmission between humans such as the infectiousness of the 
TB case, the duration and closeness of the contact, and the physical environment where the 
contact takes place. (2,3)  
In the majority of cases, TB manifests as a respiratory disease affecting the lungs which is 
referred to as pulmonary TB. (4) Symptoms occur gradually within weeks to years after 
infection with a more acute onset often observed in immunocompromised and young patients. 
The most common symptom is persistent cough as well as triad of fever, weight loss and 
night sweats.(5) However, TB is multisystem disease that can affect any organ through 
dissemination of the M. Tuberculosis to these organs from infected lungs, which results in  
extrapulmonary TB.(4,6) The most common anatomic sites of extrapulmonary TB are lymph 
nodes. Other common sites include the pleura, the central nervous system, bones, joints, 
urogenital tract, skin, ect. (7) As extrapulmonary TB can have a wide variety of clinical 
manifestations and may mimic other diseases, its diagnosis can be challenging. (6) 
As with any other infectious disease, many health-related risk factors such as diabetes, 
smoking, undernutrition, harmful use of alcohol are shown to affect the risk of infection, 
progression of the disease and treatment outcomes.(8)  However co-infection with a human 
immunodeficiency virus (HIV) is considered the most important individual-level risk factor 
for developing active TB; (9) People living with HIV  have a 16 to 27 times higher risk 
compared to the HIV-negative individuals. (10,11)  
Aside of health-related risk factors, TB disease is influenced by the socio-economic status of 
individuals which affect the risk of exposure, susceptibility of progression, and treatment 
outcomes. For example, working and living conditions, including crowding and ventilation 
influence the risk of exposure to TB while economic constraints and poverty can limit the use 
of health services and treatment compliance. (8) To no surprise, studies show that areas with 
higher socioeconomic depravation have higher TB incidence due to higher prevalence of 
socially determined risk factors for exposure and infection such as crowding, poor living 
conditions, co-morbidities that aggravate TB and financial insecurity that hampers access to 
care. (12,13) 
1.1.2 Treatment of active TB 
Active TB is normally a curable disease. Except in cases of extensive drug resistance, 
antibiotic treatment can cure the disease and hence also decrease the risk of transmission to 
others. (5)  
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In order to reduce the risk of acquired drug resistance, treatment includes a combination of 
antibiotics administered over a period of 6 to 9 months  with the following first line drugs 
normally forming the core of the treatment of drug-susceptible TB: isoniazid, rifampicin, 
ethambutol and pyrazinamide. (14) However, antimicrobial resistance is a rising challenge in 
TB management.  M. tuberculosis can be resistant to one or more of the first-line antibiotics, 
which complicates pharmacotherapy especially in case of  Multi-Drug Resistant TB (MDR-
TB), which is defined as M. Tuberculosis being  resistant to the two most important first line 
antitubercular drugs: isoniazid and rifampicin. MDR-TB complicates the clinical and public 
health management of TB considerably as second and third line drugs have to be used and 
these alternatives are more costly, typically associated with more severe side effects and need 
to be taken for a much longer time-period than the first-line treatment.(15) 
Efficacy of TB treatment is high in the absence of antimicrobial resistance. However 
effectiveness depends on many factors that can be summarized in 4 categories: 1) patient-
related factors (such as adherence to treatment, age, immunity, HIV co-infection), 2) 
pathogen-related factors (virulence of the organism, susceptibility of the strain), 3) care-
related factors (access to high-quality healthcare, monitoring and observation of treatment) 4) 
treatment-related factors (antibiotic choice, dose of drugs, side effects, drug interactions.). 
(16) Therefore, many challenges can hinder a good prognosis and compromise the success of 
the therapy.  
1.1.3 Latent Tuberculosis Infection 
Exposure to M. tuberculosis may result in a latent form of tuberculosis infection (LTBI), a 
state in which the immune system of the infected person is controlling the replication of the 
bacillus and preventing the progression to the active symptomatic and infectious disease.(17) 
In clinical term, LTBI is a condition in which a specific immune response to M. tuberculosis 
antigens is detected in a healthy subject that shows no symptoms of active TB. 
Around one fourth of the world´s population is estimated to be infected with LTBI. (18) 
These persons are not infectious. However, there is a lifelong risk of activation to 
symptomatic and infectious TB. The lifetime risk is estimated to around 5 to 10%.  Most 
activations happen within the first 5 years and around 50% within the first 2 years. The risk 
then diminishes over time, but can increase at a later stage in life due to for example disease 
or old age that impair the immune system. (19,20) 
Risk of activation is higher when the immune system is compromised for example at old age 
or in the presence of HIV co-infection, undernutrition, diabetes, renal failure, as well as a 
prolonged use of medications that weaken the immune system such as corticosteroids and 
anti-TNF-alpha.(21–23) In addition, some sub-populations are considered high risk groups 
due to their environmental and social conditions including prisoners, immigrants from high-
TB incidence countries, homeless people and illicit drug users.(24) These groups are often at 
higher risk of both exposure (e.g. due to their living conditions) and to progression (due to 
high prevalence of risk factors that weaken their immune system). They might also have 
limited access to healthcare services which delays or hinder the TB diagnosis and treatment 




Figure 1 Schematic illustration of the LTBI exposure-infection-activation cascade along with the risk 
factors 
 
1.1.4 Global burden of disease and global response 
TB is the leading cause of death from a single infectious agent and one of the top 10 causes of 
death worldwide. In 2019, an estimated 10 million people fell sick with TB disease of which 
around 1.2 million died among the HIV negative population and an additional 208 000 
among people living with HIV(PLHIV). These numbers have been steady in the last years 
showing that TB is still a huge global health concern.(9) 
The burden of TB disease concentrates in low- and middle-income countries mainly in South 
east Asia and Africa that accounted for 44% and 25% of global TB cases in 2019, 
respectively. The World Health Organization (WHO) classifies countries according to the TB 
burden, in term of incidence rate and absolute number of cases, with 30 high-TB burden 
countries accounting for 87% of the worlds’ TB cases. Only 8 of these countries (summarized 
in figure 2) contribute two third of the global cases.(9) This TB burden distribution shows the 
inequalities in prevention and health care delivery on a global level as 95% of morbidity and 
mortality occur in low- and middle-income countries where people suffer from poverty and 
suboptimal access to care.(5) On the other hand, most high income countries have a low 
burden of TB. Most of the low-TB incidence countries, meaning that TB incidence is less 




Figure 2 Global distribution of TB cases in 2019. 
 Information Source: global Tuberculosis Report 2010, World Health Organization, 2020       
*remaining 22 high burden countries list includes: Angola, Brazil, Cambodia, Congo, Central African 
Republic, DPR Korea, DR Congo, Ethiopia, Kenya, Lesotho, Liberia, Mozambique, Myanmar, 
Namibia, Papua New Guinea, Russian Federation, Sierra Leone, Thailand, the United Republic of 
Tanzania, Viet Nam, Zambia and Zimbabwe 
To address the global burden of TB and its inequalities, WHO has developed the “End TB 
Strategy” with the aim of reducing TB incidence rate by 90%, which is equivalent to reducing 
the global incidence of TB from >1 000 to <100 cases per million population by 2035. The 
strategy also aims to reduce TB deaths by 95% between 2015 and 2035, and to eliminate 
catastrophic costs for TB-affected families (defined as the total cost of TB care exceeding 
20% of the annual income of the household). (25)  
In order to reach these goals both high-burden and low-burden countries need to intensity 
their effort: In high burden settings efforts need to be broad and should focus on primary 
prevention as well as universal health coverage in order to achieve early detection of TB and 
ensuring treatment success while screening TB contacts to stop domestic transmission and 
manage LTBI in close contacts. (26)  
On the other hand, in low-burden settings, TB concentrates almost exclusively in certain 
vulnerable groups such as the homeless, prisoners and migrants from high-burden countries. 
Although society-wide prevention and universal health coverage is obviously essential in 
low-incidence countries too, special targeted screening efforts play a relatively more 
important role in these settings where the burden is highly concentrated to certain sub-
populations. TB transmission rates are usually low in low-incidence countries, and even when 
it occurs, transmission usually take the form of limited outbreaks within the household or 
sub-community around the affected individuals.(27–29) The majority of cases in low-
incidence settings result from re-activation of LTBI acquired mainly abroad, especially 
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high priority needs to be given to LTBI screening and management, including in the form of 
contact investigation, outbreak management, and screening of specific population risk groups. 
(26) The different strategies of prevention are detailed in the next section. 
Most of the high-income countries have a low TB burden.(23)  However, meeting the End 
TB strategy goals would require actions not only in the high-incidence countries but also in 
the low-incidence countries so that they also reach a 90% reduction in incidence, leading to a 
pre-elimination stage (< 10 cases per million) followed by the  elimination phase (<1 case per 
million).(25) 
1.1.5 Prevention of TB 
WHO highlights 3 levels of essential preventive action: the primary prevention that aims to 
improve the overall health of the population and address societal and individual-level risk 
factors; secondary prevention which aims to improve health through early detection and 
management of disease; and tertiary prevention which is concerned with recovery and 
rehabilitation. (31) In term of TB prevention, actions can be taken at the primary level 
through addressing underlying risk factors and social determinants, as well as through 
vaccination, while secondary prevention can be performed through early TB and LTBI 
detection and management.  
A) Primary prevention  
     1)  Addressing risk factors and social determinants   
The yearly number of TB cases can be reduced through addressing the health-related risk 
factors associated with the disease, which can include initiatives for smoking cessation, 
diabetes control and HIV prevention and control. (24) In addition, taking a multisectoral 
approach to tackle the determinants of TB infection and disease on a broader level can help in 
reducing the burden, e.g. through initiatives against undernutrition, bad housing quality and 
crowding, air pollution and most importantly poverty reduction. (32) Ending extreme poverty 
through social protection programs in high burden countries can result in substantial 
reduction in global TB burden and cross-sectional social protection approaches are important 
complements to health interventions in order to achieved the End TB targets. (33) 
      2)  BCG vaccination 
The Bacille Calmette–Guérin (BCG) vaccine is the only licensed vaccine that is used 
worldwide to prevent TB. It has been used since 1921. (34) It has been proven to protect 
against severe forms of tuberculosis in children. Therefore, WHO recommends BCG as part 
of the childhood immunization programs in high burden countries while limiting the 
recommendation to high-risk groups in low-burden settings. (24,34) However, despite very 
high BCG vaccination rates in most high burden countries the incidence rates remain high. 
(35) This reflects the low BCG efficacy in terms of impact on risk of falling ill with TB 
during adulthood. There is a pipeline of new vaccine candidates, but as yet no licensed 





B) Secondary prevention 
1) Early detection and treatment of active TB 
A cornerstone in preventing TB is the early detection and effective treatment for patients with 
active TB. In doing so, the clinical outcome will be improved and transmission of TB to 
others will decrease, leading to less TB transmission and cases. (36) As transmission is 
mainly driven by people with TB being undiagnosed or diagnosed after a long delay, which 
leads to a long period of infectiousness, effort are needed both to improve equitable access to 
care, as well as to detect cases through screening programs targeting high risk groups and 
hyperendemic communities, while ensuring that screening and detection is followed by 
prompt treatment initiation and efforts to enhance adherence and completion.(25,36–38) 
2) LTBI management 
Currently, preventing TB activation in latently infected persons cannot be effectively 
achieved through vaccination. However, prevention is possible through prevention of LTBI 
prophylaxis, referred to as TB preventive treatment (TPT), or chemoprophylaxis, which is the 
only medical intervention available at this point to prevent progression to active TB disease 
in individuals already infected with M. Tuberculosis. (24) The screening, treatment and 
management guidelines of LTBI will be discussed in the next chapter. 
1.2 LTBI MANAGEMENT 
1.2.1 Screening tools 
The tuberculin skin test (TST) was for a long time the only test for LTBI diagnosis. It works 
by identifying an immune response to tuberculin, a purified protein derivative (PPD) of M. 
tuberculosis. The individual gets an injection of PPD at the first visit then has to return after 
48 to 72 hours to measure the TST reaction on the skin. This test has some disadvantages 
such as the need for a return visit which might be problematic for hard-to-reach populations. 
Moreover, it has a low specificity especially in populations with high coverage of BCG 
vaccination as the PPD itself has a mixture of antigens that are shared by M.tuberculosis, M. 
bovis, and BCG.(39) In addition, the TST interpretation may be affected by the PPD dose 
and/or by operator variability in term of inoculation and reading of the results and in general 
there is no one cut-off that is considered to be related to positive diagnosis and the cut-off 
recommendations differ depending on the age and risk factors.(40,41)  
In the early 2000s, another family of LTBI tests was introduced: interferon gamma release 
assays (IGRAs). These blood tests rely on detecting interferon gamma produced by the T 
cells as a result of the exposure to M. tuberculosis antigen.  (39,40) Two IGRAs are currently 
commercially available, the QuantiFERON®-TB Gold Plus (QFT-Plus) (Qiagen, Hilden, 
Germany) and the T-SPOT®.TB test (Oxford Immunotec, United Kingdom). IGRAs are 
more expensive compared to TST. However, it is performed in one visit while TST needs two 
visits as well as training in reading and interpreting the results. 
Both IGRA and TST tests have limitations, as they cannot differentiate between LTBI and 
TB, they don’t differentiate between re-activation and re-reinfection and they cannot 
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differentiate who, among those with a positive test, have a higher risk of progression to 
TB.(42) Moreover, test accuracy is compromised in immunocompromised patients(43–45). 
IGRA has shown higher specificity than TST. However, there is no gold standard method for 
LTBI diagnosis and either of the tests is recommended by WHO depending on the 
availability, affordability and the practicality of testing in a specific setting.(17,46) Chest X-
ray (CXR) is not considered as an LTBI diagnosis tool, however CXR along with symptom 
screening are recommended to rule out active TB when IGRA or TST are positive .(17) 
1.2.2 Tuberculosis Preventive Treatment 
WHO recommends one of the following regimens for LTBI treatment: 6 months of isoniazid 
monotherapy, 9 months of isoniazid, or a 3-month regimen of weekly rifapentine plus 
isoniazid, or 3–4 months of isoniazid plus rifampicin, or 3–4 months of rifampicin alone.(46) 
The efficacy of these regimens vary in the literature from 60 to 90%.(47) 
Common adverse drug reactions (ADR) of isoniazid treatment are dizziness, fatigue as well 
as dermatological and gastrointestinal side effects. However, the most concerning ADR is 
hepatotoxicity, shown by an elevation of liver enzymes which can vary from being 
asymptomatic to causing liver injuries, and in cases patients experience a fulminant liver 
failure requiring a liver transplant or even causing death. (48,49) following a high elevation 
of liver enzymes and serious ADR, TB treatment is discontinued, and the risk is shown to be 
higher in older age groups. (50) 
Rifampicin-based regimens have lower toxicity including hepatotoxicity compared to 
isoniazid, however they share similar profile of ADR including discoloration of body fluids 
and serious drug interactions with other medications that patients might be using such as HIV 
medications and anticoagulants.(51,52) Therefore the WHO guidelines recommend 
chemoprophylaxis depending on age and risk factors, so that the benefits of the treatment 
would outweigh the risk of ADR. Even when risk is deemed low and chemoprophylaxis is 
initiated the guidelines emphasizes the need to monitor ADR. (46,53) 
1.2.3 Screening strategies 
Apart from the choice of diagnostic tool, the question of who to screen for LTBI is also 
critical as not all individuals infected with LTBI will activate to TB. The average lifetime risk 
of progression is between 5% and 10%, with the highest risk soon after infection. However, 
the risk varies significantly depending on risk profile of the patient. Therefore, using existing 
tools for screening and treating individuals who are at low risk of activation is likely to be 
inefficient, costly and comes with the risk of ADR of TPT that might be higher than the 
benefits. The WHO guidelines strongly recommend screening and treating selective groups at 
highest risk of LTBI infection and progression to active disease so that the benefits clearly 
outweigh the risks. According to WHO, these risk groups are mainly people who are 
household contacts of a TB patient, immunosuppressed patients such as PLHIV, patients 
initiating anti-Tumor Necrosis Factor (anti-TNF) treatment, and patients on dialysis. (10) 
WHO latest guidelines thus recommend TPT for people living with HIV, household contacts 
of confirmed TB cases and for groups with listed clinical risk factor.(9) In addition, a recent 
review by the European Centre for Disease prevention and Control (ECDC) about LTBI in 
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the European region identified key populations that might be eligible for LTBI screening 
including prisoners, homeless people and  migrants from high incidence countries. However, 
both WHO and ECDC acknowledged the current lack of evidence about which strategies to 
be adopted and which key populations to target in order to yield the highest impact at lowest 
risk with the resources available; (54) In other words, it is a question of effectiveness and cost 
effectiveness of LTBI screening strategies that has to be answered in each specific setting as 
for example a recommendation for screening migrants would depend on their country of 
origin, age and risk profile as will be elaborated on in the next chapter about migration and 
TB. 
 
1.3 MIGRATION AND TB 
1.3.1 Migration concepts 
Migration is defined by the International Organization of Migration (IOM) as the movement 
of individual(s) from their usual place of residence, whether within the same state or across 
international boarder. In the latter case the person is referred to as an immigrant.(55) A 
foreign-born is defined as a person who has ever migrated from their country of birth to the 
current country of residence.(56) 
Migration for purpose of studies or work opportunities abroad are among the common 
motivations for migration. Another common category is forced migration happening when 
people migrate due to poverty, violence or war. (57) Many of these migrants seek asylum in 
order to gain the legal status of refugee, which is defined by the United Nation(58) as 
“someone who has been forced to flee his or her country because of persecution, war or 
violence and has a well-founded fear of persecution for reasons of race, religion, nationality, 
political opinion or membership in a particular social group”. An asylum seeker is a person 
who files for a refugee status in the host country asking for the right to be recognized as a 
refugee and receive legal protection and material assistance.(58) Therefore, an asylum seeker 
is an individual who is seeking international protection, even though the person might not be 
ultimately recognized as a refugees. These legal differences are important to highlight as 
laws, rights and legislations may differ according to the legal status of the individual in a 
certain host nation.(55) 
The current trend of migration is mainly from low-income countries to high-income 
countries. Taking the European region as an example, over 82 million immigrants lived in the 
continent in 2019, a 10 % increase compared to the figures of 2015 when the arrival of 
refugees via the Mediterranean route led to a huge pressure on the asylum seeking process in 
the EU and affected the functioning of the Schengen area as border checks were implemented 
between many member states. (57,59) Since then, immigration continues to be a political 
issue in Europe with attitudes toward immigration remaining polarized, which affect the 
policies of integration, access to essential services including healthcare as well as the 
physical, mental and social well-being on immigrants across the continent.(57,60) 
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1.3.2 Impact of migration on TB globally 
Migration can affect TB epidemiology especially in high-income/low-incidence countries 
that receive migrants from low-income/high-incidence countries. These migrants face 
increased risk of TB exposure, poor treatment outcome and higher risk of antimicrobial 
resistance, all exacerbated by many factors at pre-departure, during transit and after arrival in 
the host country. (61,62) 
In their home country, their health status, access to care and possible experiences of conflicts 
or disasters play a major role in their pre-departure health and TB risk exposure, especially 
since many of the migrants are from high-TB incidence countries. (61)  
Especially relevant in cases of forced migration, individuals can be at increased risk of TB 
due to the transit conditions and the diversity of groups moving together in similar pathways, 
often under unsafe and overcrowded conditions. Therefore, even migrants from low- or 
medium-incidence countries might be at high risk of TB exposure due to contact with other 
migrants along the migration trajectory. (61) 
Finally, when arriving and settling in the host country many factors shape the risk of TB 
disease and treatment-seeking behaviors such as legal status of the migrant, the knowledge 
about the disease and its symptoms, the access to healthcare and screening programs, the 
working and living conditions, in addition to cultural and language barriers that might 
influence any screening or treatment outcomes. (61) 
In general, studies have linked the high-TB burden in migrant population mainly to the 
activation of LTBI acquired in home country or in transit before arriving to the host country. 
The other mechanism of TB disease can be through acquiring the infection post-arrival 
through local transmission, which has however been shown to be low in low-incidence 
countries also among migrants.(28,63–65)  
1.3.3 Migrants and TB/LTBI screening in low-incidence countries in Europe 
and elsewhere   
Based on what has been discussed above, it is no surprise that most of the TB burden in 
European countries is concentrated among foreign-born populations and migrants. In these 
mostly low-TB incidence countries, the TB rates continue to decrease in native populations 
while this decrease is slower in migrant populations and the proportion of foreign born 
among TB patients is therefore increasing. (66,67) in 2015, the proportion of foreign-born 
among TB cases was more than 50% in the majority of the low-incidence countries (20 out of 
30) , and this proportion exceeded 80% in several countries such as Cyprus, Iceland, Norway 
and Sweden, which shows that TB burden in these countries is heavily linked to 
migration.(66) 
In its report “tuberculosis surveillance and monitoring in Europe 2020”, the ECDC highlights 
that despite the decrease in TB incidence, the burden of TB in the European region is still a 
major public health concern that should not be underestimated especially since it affects 
mainly vulnerable group such as migrants. (68) Most countries of the European Union have a 
national TB control plan and 80% of these countries report that reaching vulnerable 
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populations is a priority action, including asylum seekers, refugees and undocumented 
migrants.(69) 
A WHO framework for TB elimination in low incidence countries has been developed which 
highlights 8 priority areas including the need to address vulnerable and hard-to-reach groups 
with emphasis on migration and cross-border issues including LTBI and TB screening and  
treatment for these high risk groups, optimize prevention and care of resistant TB and 
screening for TB and LTBI in contacts and high risk groups while providing adequate 
treatment.(29) However, given the likely high number needed to screen and low impact of 
screening all migrants for TB and LTBI, and potentially high cost, indiscriminate screening is 
likely to not be cost effective. Therefore, most countries adopt more selective strategies 
mainly based on the type of migrants and TB incidence in their country of origin according to 
the WHO classification.(64) Due to limited evidence, neither WHO nor ECDC provide 
guidance on exactly which migrants potentially to target with TB or LTBI screening, e.g 
based on type of migrant, TB incidence in the country of origin, age or presence of other risk 
factors. It remains an important research question which TB or LTBI screening strategies are 
the most effective and cost-effective.  
TB screening for migrants 
Pre-migration screening of TB, for example as part of the process to apply for a visa, has 
been shown to reduce incidence of TB in people from high-incidence countries shortly after 
arrival in the host country. However, the impact on transmission in the host country of such 
screening is still unclear(70). Moreover, such screening may not be feasible in many cases 
especially among refugees and asylum seekers. There is no evidence in the literature on 
epidemiological impact in the host country of systematic screening for active TB among 
migrants at the port of arrival and in general the evidence in support of post-arrival, both in 
terms of effectiveness and cost-effectiveness is weak. (71,72) The main unresolved question 
is if systematic screening improves early diagnosis of active TB as compared with efforts to 
ensure that people with TB symptoms have easy access to health care services and good 
knowledge about when and how to seek care. Both WHO and ECDC emphasize that policies 
targeting TB control among migrant, especially refugees, asylum seekers and undocumented 
migrant must be tailored to the risk factors of these population and implemented with 
appropriate social and financial support.  
A further limitation of screening for active TB is that only those people who have activated at 
the time of screening can be detected. Since most incident cases activate at some point after 
arrival, the majority of cases will be missed with a one-off screening soon after arrival. As the 
majority of TB cases in these populations result from LTBI activation, focusing on LTBI 
screening and treatment seems to be of a higher priority than screening for active TB, but it 
also comes with challenges (29,46,70,73), which is further discussed below. 
LTBI screening 
There is strong evidence that LTBI screening and treatment in contacts and individuals with 
certain co-morbidities (like immunosuppressive diseases and medications) is effective and 
cost-effective and it is in accordance with the recommendations of WHO.(29,72,74) 
However, widening screening to all migrants from high-income countries is not yet supported 
 
 11 
by strong evidence as benefits of systematic careening and treatment might not outweigh the 
harm, or may not generate sufficient impact at acceptable costs. Therefore, such screening is 
only conditionally recommended by WHO and when done should be targeted to those with 
highest risk while adapting screening strategies to local TB epidemiology and availability of 
resources.(46,72) As discussed above, WHO and ECDC does not provide precise advice for 
this targeting.  
Broad conditional recommendations from international expert organizations in combination 
with the availability of a variety of tests, risk groups and treatment options has led to a wide 
range of LTBI screening strategies for migrants in different host countries. Another aspect 
that differs among countries is the timing of the screening: while some countries do an entry 
screening which means screening for LTBI immediately at the entry to the new country, other 
countries adopt the post-entry screening as part of the access to specific services such as 
primary health care service, job application or the first contact with the health care 
services.(75)  
Decisions about LTBI screening policies in Europe need ultimately be based on the local 
context, cost considerations as well as the TB epidemiology in the specific setting.(72) A 
review summarizing the policies of TB/LTBI screening in the EU countries showed a large 
variation of strategies between these countries with different criteria based on the type of 
migrants and various thresholds for TB incidence in the country of origin, age and risk 
factors.(76) For example in Belgium, only asylum seekers younger than 5 years old and 
pregnant women get screened for LTBI with TST, while in Norway all migrants younger than 
15 years old and migrants between 18 and 34 coming from countries with TB incidence more 
than 200/100 000 get tested by IGRA. In Germany there is no official LTBI screening. (77) 
Sweden has another strategy for LTBI screening that will be discussed in the next chapter.  
 
1.4 TB IN SWEDEN 
1.4.1 TB epidemiology in Sweden 
Sweden is a low TB incidence country that experienced a substantial decline in TB rates in 
the 20th century. The lowest incidence rate registered was in 2003, about 400  cases or 4.6 
cases per 100 000 inhabitants (figure 3). (78) The incidence has since continued to decrease 
among the Swedish born (now less than 1 case per 100 000) while it has fluctuated among the 
foreign born following shifting immigration trends. The large influx of asylum seekers in 
2015 affected the total incidence in the country, which reached a peak of >800 (8.5 per 100 
000) in 2015, and thereafter TB incidence has again declined as migration diminished in line 
with changing migration policies. In 2019, the incidence was 4.8 cases per 100 000. Thus, the 
total TB incidence in Sweden has in recent decades mainly been determined by the migration 
flows from high incidence countries. The proportion that are foreign born has remained 
around 90% throughout the period (37,78). Most of the TB cases currently are individuals 
aged between 15 and 40 years, which is a reflection of both the global TB epidemiology and 
age profile of migrants from high burden countries. There is limited domestic transmission 
within the risk groups and even lower outside of these groups and most of the cases occur 
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through activation of LTBI, which is in line with evidence from other low-incidence 
settings,.(28,78,79) 
 
Figure 3 Number of notified TB cases in Sweden from 1990 till 2019. Source: The Public Health 
Agency of Sweden, 2020   
 
1.4.2 TB and LTBI screening in Sweden 
In Sweden, LTBI screening and treatment is currently recommended for four main risk 
groups which are presented in table 1.(80) First, contacts of a TB case are screened and 
followed though a mandatory contact tracing policy. Recently infected individuals are at a 
high risk of developing active TB and detecting it at an early stage can hinder the activation 
and the further spread of the infection. Another risk group are patients on immunosuppressive 
treatment as the impaired immunity leads to an increase risk of TB activation. This patient 
group includes patients starting on anti-TNF alpha inhibitors, transplant recipients, persons 
undergoing regular dialysis. Recommendation in Sweden, aligned with international 
guidelines also emphasize the need to screen PLHIV due to the high risk of co-infection with 
TB, therefore PLHIV is another major risk group for LTBI screening. 
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    Table 1 LTBI screening policies for different target groups in Sweden (81) 
 
A recent Swedish study has shown the increased risk of TB activation in connection with 
pregnancy, especially in the 6 months post-partum which is in line with the conclusions 
drawn from a similar Study in the United Kingdom (UK). (82,83) Before the new guidelines 
of 2020, there were no firm conclusions about the need to screen pregnant woman and only 
some regions in Sweden, including Stockholm, started screening pregnant women born in 
high-incidence countries for LTBI. However, the new recommendations highlights the need 
to screen this group. (81) 
The largest risk group in the country that is considered for LTBI screening are recent 
migrants coming from high-incidence countries, many of whom can be assumed to have had 
contact at some point with a TB case in their home country or along the migration route. 
Sweden has a policy of screening migrants from countries with a TB incidence of more than 
100 /100 000 as well as migrants with high risk of TB exposure (e.g in refugee camps or 
prisons during the migration process) with TST or IGRA. IGRA/TST screening, together 
with symptom screening is used as a strategy for detecting both active cases and LTBI in 
Sweden, while most other low-incidence countries do chest X-ray screening for all, and then 
some add LTBI screening with TST/IGRA. In Sweden, a chest X-ray is done after a positive 
IGRA test to further screen for active TB.(84,85) 
The screening takes place as part of a voluntary health examination for asylum seekers (and 
quota refugees and some joining family members) arriving to Sweden. Thus, this screening is 
not offered for all types of migrants; however, the new guidelines of the public health agency 
of Sweden in 2020 has added a note about the need to screen also people from countries with 
a high TB incidence regardless of their legal status and the reason of migration. Hence, 
people moving for studies or work should also be considered a risk group eligible for LTBI 
screening, although there is as yet not specific programme or infrastructure set up for this, 
meaning that such screening should be integrated into general health care for this group. (81) 
All asylum seekers who attend a health examination, regardless of TB incidence in the home 
country, are screened for TB symptoms and referred for chest X-ray if symptomatic, in order 
to identify active TB. Asylum seekers eligible for LTBI screening are offered screening and a 
positive IGRA or TST test is followed by an X-ray. A positive X-ray leads to referral to TB 
specialist while a negative X-ray requires the assessment of age and risk factors to decide 
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whether the individual should be referred to a specialist or not. This process of screening is 
explained in detail in one of the related articles of this thesis and summarized in a flow chart 
extracted from that study (figure 4). (84) The procedure and the challenges around the health 
examination are the focus of the next section. 
 
Figure 4  Flowchart of tuberculosis screening of asylum seekers in Stockholm region 2015-2018. (84) 
 
1.4.3 Health examinations in Sweden 
Asylum seekers in Sweden are entitled to necessary medical care as provided by the Swedish 
reception of asylum seekers’ act (LMA). This care is restricted to medical and dental care that 
cannot be postponed, childbirth and maternal care, contraceptive advice and abortion. 
Asylum seekers under the age of 18 are entitled to the same health care as any citizen and the 
same applies to asylum seekers who have been granted a residence permit, referred to as 
refugees. (86) 
In Sweden, all asylum seekers, as well as quota refugees and some reunified family members 
including all children of school age are invited to a voluntary post-arrival health examination 
(HE), within which TB screening is also performed.(87,88) Asylum seekers who have 
received refugee status are also eligible for a HE up to two years after arrival. Migrants 
coming for other reasons such as studies or work as well as most late-arriving relatives are 
not invited to a HE. The HE is offered in the region/county they are resided. (86,89)  
This examination is free of charge and voluntary. Some data indicate that the uptake of this 
service varies between regions in Sweden due to many obstacles in the organization and the 
communication between healthcare, authorities and the asylum seekers. (90) Previous 
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research in Sweden highlighted that poor communication, lack of clarity about the purpose of 
this examination and the lack of information about this service contributes to the low 
attendance. (91–93) 
1.4.4 Knowledge gaps concerning HE and LTBI screening in Sweden 
Barriers for participation in the HE can be problematic for TB control because the health 
examination is the first contact for these migrants with the health care system and the main 
opportunity to screen them for TB and LTBI. Understanding migrants’ experiences with the 
health examination procedures, content and perceived value is critical in order to improve this 
health service and hence improve the entry point for infectious disease control among this 
group. This topic has been explored qualitatively and quantitatively in different regions  of 
Sweden and results emphasized the need to ameliorate the health examination to tackle 
communicable and non-communicable diseases among asylum seekers.(93–95) This topic 
will be discussed further in the results and discussions of this thesis.  
Neither the effectiveness nor the cost effectiveness of the current screening strategy has been 
evaluated prior to this doctoral project, although TB and LTBI screening has been part of the 
HE procedures since the mid-1990s. Moreover, there have been no previous systematic 
monitoring of the screening coverage, screening results, proportion of those screened positive 
referred for further evaluation or proportion started on treatment or completing treatment. The 
methodology of cost effectiveness analysis will be discussed in the next chapter. 
 
1.5 HEALTH ECONOMICS IN TB 
1.5.1 Economic burden of TB  
TB disease leads to economic burden on different levels: healthcare sector, individuals as 
well as societies, which will be discussed below. 
a) TB economic burden on healthcare  
Despite being a preventable disease, TB still causes a high burden on healthcare systems in 
term of costs and resource use, especially in low- and middle-income countries. Some 
governments spend large amounts on TB care and prevention while other countries cannot 
afford it and rely on development assistance.(24,96) The structure and performance of the 
health system, including service availability, health care fees and quality of care affect the 
health seeking behaviors of individuals, access to care and adherence to treatment.(97) 
Consequently, insufficient capacities of healthcare can limit the effectiveness of TB 
interventions and hinder the implementation of supportive programs for patients.(98)  
TB economic burden is not to be neglected even in high-income, low-incidence setting. A 
literature review in the European region showed high costs of TB treatment across the 
continent (99) A costing study from the United States of America (USA), another low-
incidence country, showed similar high costs attributed to hospitalizations, emergency 
department visits, and outpatient visits in the first year.(100) Therefore, investing in 
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prevention may help reduce the burden on the health systems in both high- and low-resource 
settings. 
b) TB economic burden on individuals 
TB is considered a disease of poverty, which means belonging to the poor and to vulnerable 
groups (including many migrants) increases the risk of infection, progression to disease, poor 
treatment outcomes and severe socioeconomic consequences of the disease. Falling ill with 
TB can accentuate a spiral of poorer health, increased medical costs, decreased income which 
eventually can entrench poverty. (101) In high-burden countries, TB can drive people into 
poverty with research showing that from 27% to 83% of these patients experience 
catastrophic costs and around 50% of them obliged to sell assets or take loans as a result of 
TB disease.(24) Out-of-pocket payments are shown to be high in resource-constrained 
countries, which poses a challenge for accessing care and adhering to treatment and as 
consequence compromising the progress toward achieving the End TB strategy goals. 
(96,102)  
In high income countries where TB treatment is usually covered under universal health 
coverage schemes (funded through taxes or social insurances schemes), the out-of-pocket 
cost of treatment itself might not be an obstacle. (101) However, patients can still need to 
cover direct non-medical costs such as transportation. This out-of-pocket payment can be an 
economic burden especially in migrants’ populations as shown by a Dutch study highlighting 
that out-of-pocket payment constituted 3% of the annual income of TB patients with migrant 
background. (103) A major concern is the income and productivity loss due to TB (discussed 
under the next paragraph. 
c) TB economic burden on Society 
Individuals spend time seeking care, being hospitalized or looking after someone else who is 
sick (caregivers and parents of sick children) instead of working and being productive. 
Therefore, TB is also associated with productivity loss that goes beyond individual economic 
burden to the society in general. (104,105) As with the other consequences, productivity loss 
is even more of an economic threat in low-income countries. For example, a cost of illness 
study conducted in the African region shows that the sizeable burden on the economy is 
mainly due to productivity loss. These results highlight the need for better prevention 
programs in order to decrease the economic burden of TB disease.(105) As the economic 
burden and the loss of productivity cannot be ignored, social protection interventions are 
essential to prevent or alleviate the financial risks and losses due to TB and it can contribute 
to better treatment adherence and clinical outcomes.(106)  
According to WHO, the majority of TB patients in the European region are in the 
economically productive age group aged 35 to 44 years. Hence morbidity and mortality due 
to TB represents a loss of human capital and has a direct effect on the household economy 
and the well-being of the individuals. (24,107)  
 In sum, TB can have devastating economic consequences on individuals and societies in 
low- and middle-income countries. All these financial burdens are exacerbated in case of 
MDR-TB, where costs are shown to be very high for patients, the health care sector and 
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society (96,108,109). Hence, societal costs in general should not be ignored and therefore 
limiting the estimations for TB costs and potential savings to a healthcare perspective only 
seems to underestimate the actual burden and costs of TB. (104) 
1.5.2 Cost-effectiveness analysis  
Resources in healthcare are finite in both poor and rich countries, whether is term of 
infrastructure, consumables or human resources. Therefore they need to be used in the most 
efficient way.(110) Limited healthcare resources is the foundation of  health economics, a 
field that is concerned with how health systems and societies allocate its resources among 
different alternatives and provide tools to answer the questions of what goods and services to 
produce, how to produce them and who shall receive them. (111)  
One of the tools for health economic evaluation that is widely used in decision making is 
cost-effectiveness analysis (CEA).(112) It is an analysis used to compare the value of 
different intervention and its outcomes in term of creating better health and longer life for 
people or the return on investment in monetary term.(110) CEA results are usually presented 
in term of incremental cost-effectiveness ratio (ICER), which is a ratio with the denominator 
representing the health gain from an intervention and the numerator reflecting the marginal 
costs of that health gain. For example, if the health gain of an intervention “A” implemented 
in Sweden is measured as additional averted TB case then ICER would be expressed in term 
of additional Swedish Kronor spent per additional averted case.(110,113) As such, economic 
modelling is used to predict the future costs and effects of alternative interventions in order to 
inform policy about alternatives for investments. In addition, these models help deal with 
uncertainties about different parameters by performing sensitivity analysis in which 
assumptions can be made when data is not available or controversial. (110)  
As with other diseases, management and prevention of TB can be done through different 
strategies across different target groups. In term of evaluating LTBI screening and treatment 
strategies, the many possible variations in different components such as target population, 
diagnostics and treatment options discussed previously is a reason for why modelling can be 
helpful in assessing different scenarios. At the same time the many permutations of options 
can impose a challenge in the cost-effectiveness modelling. In addition, literature reviews in 
the field have highlighted the variations in term of economic perspective, economic inputs 
and measured outcomes. These inconsistencies and different approaches make it difficult to 
reach a firm consensus about both the most appropriate modelling approach and the most 
cost-effective screening strategy. (114–116) 
An economic evaluation is performed from a specific perspective that will determine the type 
of costs included in the analysis. (110) The analysis can be performed from the healthcare 
provider perspective including the cost paid by the healthcare system or a third-party payer. A 
broader societal perspective can be used to include the direct and indirect costs for patients or 
households, including the time lost from work while seeking treatment or participating in a 
health intervention. Productivity loss is an important part of the societal perspective costs, 
which can be related to both the opportunity cost of time lost being in care, as well as reduced 
labor participation due to illness, disability, stigma and discrimination. (110) The adoption of 
a societal perspective raises a big measurement challenge and it might be tempting to omit 
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items from consideration (112). However, in the case of LTBI screening, preventing an active 
TB case would save many hours of productivity loss associated with disability and time lost 
for diagnosis, treatment and follow-up. Therefore, it would be recommended to include it in 
the analysis, especially in Sweden where the Swedish Dental and Pharmaceutical Benefits 
Agency (TLV) recommendations state the preference for a societal perspective. (117) 
Cost effectiveness in term of LTBI screening and management among migrants needs to 
heavily rely on local indicators and TB epidemiology in the specific setting. (115) One of the 
critical empirical data is the cascade of care of LTBI management which will be discussed in 
the next section. 
1.5.3 Cascade of care 
A screening strategy needs to define the timing of screening, the target group, the testing 
algorithm, the eligibility and exclusion criteria for treatment, as well as the required 
interventions to enhance coverage and completion of each step in the screening and treatment 
cascade. The first cascade step is the screening, followed by completing the medical 
evaluation, recommending treatment when needed, initiating and completing the treatment. 
The degree of completion of each cascade step influences the effectiveness and cost-
effectiveness of the strategy. It is therefore important to analyze each step in the multi-staged, 
complex path of LTBI screening and treatment. (118) A CEA that uses local empirical 
cascade of care data will enable a realistic assessment of the present performance and 
efficiency. At the same time, it can identify cascade gaps that influence cost-effectiveness 
while a sensitivity analyses can help identify cascade improvements that could make the 
screening more cost-effective.   
A systematic review and meta-analysis of study-level observational data from various 
screening settings and strategies concluded that there are often major losses at different steps 
in this LTBI screening and treatment cascade. The meta-analysis concluded that out of all 
individuals intended for screening, 35% were positive and recommended for treatment but 
only 18,8% of them completed the treatment. (119) Another systematic review concluded that 
initiation and completion rates of LTBI treatment varies within and across different risk 
groups and these rates are frequently suboptimal highlighting the need for adherence 
enhancing interventions.(120) This study reported that among immigrants the initiation of 
TPT varied between 23 and 97% among people diagnosed with LTBI while the treatment 
completion rate when started varied between 7 and 86%.(120)  
This wide variation highlights the need for local data about LTBI management in order to 
evaluate any national or local policy in term of effectiveness and cost effectiveness as these 
parameters should be included in the economic modeling. Another parameter that has a major 
effect on the cost effectiveness results is the measured outcome with the health-related quality 




1.6 HEALTH-RELATED QUALITY OF LIFE  
1.6.1 Basic concepts  
Cost effectiveness studies of preventive TB interventions can use averted TB cases as an 
outcome. However, a widely used alternative is quality-adjusted life years (QALY) based on 
measurements of HRQoL. But what is HRQoL? And how to obtain QALYs? 
Developments in health care and medical technologies has resulted in treatments extending 
life sometimes at the expense of quality of life (QoL) or improved QoL without extending 
life. Therefore, mortality rates were are not enough to account for the effect of health 
interventions as it fails to grasp any QoL improvement and cannot be used to assess some 
interventions like palliative care programs. A health outcome is needed to accommodate for 
the effect on QoL as well as the extend of life. Hence, the concept of QoL has become center 
piece for health economic evaluations. (110,121)  
QoL can be defined as ‘‘an overall general well-being that comprises objective descriptors 
and subjective evaluations of physical, material, social, and emotional well-being together 
with the extent of personal development and purposeful activity, all weighted by a personal 
set of values’’(122). While this definition seems like an all-inclusive concept including all 
factors affecting a persons’ life, HRQoL accounts only for the dimensions that can be 
changed by a disease or treatment and therefore it accounts for the dimensions affected by 
health. (121)  
To understand the impact of healthcare interventions and compare across different areas, a 
common measure needs to be used, a measure that encapsulate the intervention effect on both 
the length of life and on the HRQoL; hence the QALY has been developed to be used as an 
outcome in health economic. (123) HRQoL is defined as values assigned to different health 
states. These values or utilities can be used to calculate QALY which is a value on a scale (0 
to 1) with 1 being equal to full health (no health problems), zero equal to death and values in 
between 0 and 1 reflect a loss of HRQoL (attributed to a health problem). Health state worse 
than death can be also reflected by a negative value. (110) Through having this health 
measurement as a main outcome of a cost-effectiveness analysis, comparison can be done 
across health interventions in different areas in healthcare, forming a tool for policy making 
and resource allocation. (110) 
1.6.2 HRQoL instruments 
HRQoL is measured through validated instruments that can be generic or disease-
specific.(110,123,124) Generic instruments can be used among any population regardless of 
the presence of a health condition or disability while the disease-specific instruments are used 
among a specific group of patients assessing specific symptoms as well as functional and 
overall health.(110,125) The most commonly used generic instruments include EuroQoL 5 
dimensions (EQ-5D) and the short form health survey with 36 items (SF-36), which includes 
many questions (dimensions) and respondents choose a response from a set of alternatives for 
each question.(125)  
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EQ-5D is a validated HRQoL instrument developed by the EuroQol Group.(126,127) The 
instrument includes a  descriptive system of five dimensions (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression) where the respondents choose one option 
for each dimension.(126) Depending on what answer the respondent chose for each 
dimension, he/she will obtain a QALY score generated from these 5 chosen answers, based 
on a specific value set decided for the analysis. The instrument  is available with 3 levels 
(EQ-5D-3L), meaning that for each domain the participant choose one of 3 options to 
describe the health state (no problems, some problems, extreme problems), or with 5 levels 
(EQ-5D-5L) in which the 5 levels are available (no problems, slight problems, moderate 
problems, severe problems, extreme problems). In addition, the instrument includes a visual 
analogue scale (VAS) where individuals rank their health from 0 to 100 on a scale. (126)  
Another widely used instrument is SF-36, a validated instrument of 36 questions divided into 
8 subscales accounting for physical, social and mental well-being. These subscales are: 
general health, physical function, bodily pain, vitality, role-physical, social functioning, role-
emotional as well as mental health.(128) For each of the subscales, a score from 0 to 100 is 
obtained based on the answers of the related questions with zero referring to complete 
disability and 100 is equivalent to no disability.(128,129) In addition to reporting the scores 
of each subscale, a common way to present the result of this instrument is to calculate 2 
scores: a physical component summary and a mental component summary which can be 
obtained through mathematical calculations. (129) However, these values are not QALYs and 
cannot be used in health economics, therefore a variation of SF-36 was developed, SF-6D 
that can be used to calculate a QALY value ranging from 0 to 1 and adapted in economic 
models. (129) 
1.6.3 HRQoL and TB 
TB disease affect the psychological, functional, economic and social wellbeing of individuals 
and therefore HRQoL is an important adjunct outcome in TB programs and interventions, in 
addition to standard outcomes such as cases averted, cure and survival.(130) QALY has been 
used in economic evaluations of TB programs as it suits the societal perspective and it can 
capture several dimension of the effect of the disease, including disability, psychological 
distress, stigma, side effects of treatment among other factors.(110,131)  
Many factors influence the HRQoL which can be related to patient characteristics, such as 
demographic characteristics, and clinical presentation, or related to the treatment of TB 
including health system and health financing factors. (130) These factors are summarized in 




Figure 5 Summary of factors affecting the quality of life of Tuberculosis patients (130) 
Due to the complexity of the disease and the interactions between the different factors 
mentioned above, it can be challenging to quantify impairment of HRQoL due to TB. A 
recent review showed wide variation in results across countries and patient groups using 
different instruments. However, the review highlighted that productivity loss, psychological 
impact and social stigma are common reasons affecting the HRQoL of TB patients. (130) A 
variety of instruments are usually used to assess HRQoL in the TB field. There is no well-
validated TB-specific instruments and most studies have used generic instruments,  mainly 
SF-36 and EQ-5D. (132) However, most studies have been conducted in high-incidence 
countries and very few studies have been conducted in countries with low incidence where 
better data is therefore needed due to expected difference in the setting- and patient-related  
profiles. 
Although patients’ health status improves with treatment, active TB is associated with a 
decrease in the HRQOL that might not be restored until months after the end of treatment, or 
may persist for long periods if there are permanent sequalae from the disease, with physical 
health possibly recovering quicker than the mental health components.(130,132)  
Despite being asymptomatic, a diagnosis of LTBI may cause anxiety and raise concerns 
among patients in addition to the risk of adverse drug reactions of preventive treatment. (132) 
This diagnosis may also be miscomprehended as active TB which can increase stigma and 
psychological stress. (133,134) All these factors can theoretically impair the HRQoL of 
patients in term of physical, mental and/or social well-being. Nevertheless, there is scarcity of 
studies assessing this topic in the literature. Canadian and American studies have concluded 
that there is no significance difference in the HRQoL between LTBI patients and the general 
population and hence suggested no decrease of HRQoL in economic evaluation.(135,136) 
However, these studies do not provide deep understanding of the physical, social and mental 





1.7 RATIONALE OF THE THESIS 
 
In Sweden, LTBI screening has been offered for decades to some migrants from high-TB 
incidence countries, but this screening strategy has never been previously evaluated. More 
generally, there is an urgent need for research on LTBI screening for persons migrating from 
high- to low-incidence countries in order to guide future national and international policy and 
resource allocation. There is little international consensus on which migrants to screen, when 
and how. WHO and ECDC conditionally recommends such screening but do not elaborate on 
the conditions or modalities to consider due to a very weak evidence. As a consequence, low-
incidence countries, including those where most TB cases are among foreign-born persons, 
use very different screening approaches and many countries do not perform any migrant 
LTBI screening at all. There is a need first to describe the LTBI screening and treatment 
cascade and to identify the obstacles and opportunities to complete the cascade in order to 
identify areas that need to be improved.  
In the Swedish context, participation in health examination is of particular interest as it is the 
first contact for asylum seekers with the LTBI screening procedures. In addition, there is a 
need to conduct economic analysis in order both to assess the overall cost effectiveness of the 
current screening strategy, as well as to determine the most cost-effective targeting of 
screening. There is a lack of evidence in the literature about cost effectiveness of LTBI 
screening in general and no CEA has previously been done on LTBI screening in Sweden. 
Hence the idea of this thesis project. Despite the availability of some CEA studies in low-
burden settings, the variation in methods is a challenge that this project also addresses 
through a review of the methodology and development of a framework for such analyses. 
Therefore, this project not only generates locally relevant cost-effectiveness data but also 
helps develop better and more standardized economic evaluation methods for assessing 
screening of LTBI in migrants.  
Finally, there are very few studies reporting the HRQOL of migrants with TB or LTBI and a 
complete lack of data from the European countries. Therefore, while the HRQoL component 
of this thesis contributes to the CEA in Sweden, it may also serve as a reference for future TB 










1.8 PROJECTS RELATED TO THIS PHD 
 
This PhD is part of a larger research project about tuberculosis screening in Stockholm. The 
work involved two departments at Karolinska institutet - the Department of Global Public 
Health and Department of Medicine, Solna, The Karolinska University Hospital, the 
Department of Communicable Disease Prevention and Control, Stockholm Region, and the 
Public Health Agency of Sweden. The overall aim of the projects was to assess the migrant 
TB and LTBI screening strategies in the Stockholm Region through a mix of qualitative and 
quantitative studies in order to both judge the value of the present screening strategy, as well 
as to identify areas of improvement, with special attention to how to implement screening, 
referral and treatment to maximize access and adherence. The PhD project of Joanna Nederby 
Öhd provided data about screening coverage, screening results and completion of the cascade 
of care data (84), which was used to parameterize the CEA model in the present doctoral 
project with local empirical epidemiological and implementation data. The author of the 
present thesis was involved in the design, interpretation of results and writing up the 
manuscript for the cascade analysis, and was a co-author of that paper, although that paper is 
not included in the present thesis. Qualitative work and assessment of HRQoL for the present 
doctoral project was coordinated with Lena Jansson who is studying LTBI screening for 
pregnant women with migration background in Stockholm (137). The author of the present 
thesis was involved in the design, data collection, analysis, interpretation of results and 
writing up the manuscript and was the second author of that paper (128), although that paper 
is not included in the present thesis.  
Beyond the Swedish setting, this doctoral project was linked to a European project (E-
DETECT TB) funded by the EU-CHAFEA, which focused on building an international 
migrant TB screening database through extracting data about TB and LTBI screening and 
cascade of care in four European countries: Sweden, Netherlands, Italy and UK.(84) As part 
of E-DETECT TB, economic assessment of LTBI screening in these countries were 
performed mainly using the model developed within this thesis. Comparison of methods and 
results between countries is planned for the future, however it is beyond the scope and the 
timeline of this PhD project. 
This project received funding from the Swedish Research Council for Health, Working Life 
and Welfare (grant 2015-00304), the Swedish Heart and Lung Foundation (grant 2016-0508) 








2 RESEARCH AIMS 
 
The aim of this doctoral project was to determine the cost-effectiveness of the current strategy 
of screening for LTBI among asylum seekers/migrants in Stockholm. Ultimately, the project 
aims to provide policy recommendations to improve and rationalize LTBI screening in 
Stockholm and Sweden. 
 
The specific research objectives were to: 
1) Review and assess the methodology of economic modelling of LTBI screening, understand 
the major methodological determinants of variability between models and develop a 
framework for CEA of LTBI screening for asylum seekers in Stockholm. 
2) Understand the experiences of asylum seekers attending a health examination in 
Stockholm, in order to identify gaps and need for improvements. 
3) Explore patient experiences with diagnosis and treatment of LTBI as well as their HRQoL 
and the factors influencing it. 
4) Quantify the HRQoL of TB patients in Stockholm. 
5) Assess the cost effectiveness of the current LTBI screening strategy among asylum seekers 
in Stockholm compared to a scenario of no screening. 
 
These objectives are achieved thorough the different studies included in this doctoral thesis 
and summarized in figure 6 which shows the LTBI screening pathway, the aim of the studies 







Figure 7.  LTBI screening process and the distribution of the thesis objective along its pathway. 




























































































































3 MATERIALS AND METHODS 
3.1 OVERVIEW OF METHODS BY TOPIC 
3.1.1 Experiences of Health Examinations (study II) 
Study design 
Through a qualitative design, researchers can collect and analyze expressive information 
about values, experiences, motivation and beliefs that orient behaviors that can be difficult to 
captured with quantitative research techniques.(138) Consequently, this study designed was 
deemed suitable to explore the experiences of migrants with HE which is the aim of paper 2. 
Semi-structured interviews were conducted with migrants based on an interview guide that 
was developed and piloted before conducting the study. The guide focused on exploring the 
experiences of the respondents throughout the HE. The guide was revised and ameliorated 
throughout the process after conducting the first few interviews. The aim of the revision was 
to include topics of special interest for the respondents that were not initially covered by the 
interview guide.  
Study setting and participants 
Participants were recruited among migrants in Stockholm county based on the following 
inclusion criteria: 
1) Legal status: being an asylum seeker or a refugee 
2) Age: 16 years or older 
3) Fluency in one of the following languages: Arabic, French, Swedish, Somali, Dari or 
Pashto 
Participants were recruited from four different settings around Stockholm county: 
1) A language café in the Northern part of Stockholm 
2) A Swedish language course in central Stockholm 
3) An asylum accommodation in the southern part of Stockholm 
4) Through contacts that previously worked with asylum seekers in Stockholm 
Data collection  
Interviews were conducted between November 2016 and February 2017 by the PhD 
candidate. A translator assisted during the interviews in Dari and Pashto. Interviews were 
recorded and lasted between 20 to 25 minutes targeting mainly themes based on the interview 
guide however probing techniques were used to help the respondents elaborate on their ideas 
and express their main concerns and observations. Interviews were conducted until data 






The interviews were transcribed verbatim by the PhD candidate in English language after 
listening to the recordings several times to ensure complete understanding of the transcripts. 
The next step was to read the transcript with the senior researcher of the paper and code 
manually the transcripts and these codes lead to potential categories that were discussed and 
fitted into a larger theme. Therefore, a thematic analysis was used throughout the process as 
codes were grouped into categories that matched sub-themes and themes. (139) However, the 
themes were not created by the authors, rather they were pre-determined based on the 
availability, accessibility, acceptability and quality (AAAQ) framework. (140) The main 
categories fitted into one of the four domains of the framework (which are explained in table 
2) that was developed under the human rights convention that Sweden ratified and is legally 
bound to implement. In addition, this framework allows assessment of the health examination 
in a way that answers the research questions of the study. 
     Table 2  Definition of the AAAQ framework domains 
 
 
3.1.2 Health-related Quality of Life (study III and IV) 
Study design  
HRQoL data was performed through cross-sectional design for LTBI patients and a 
longitudinal design for TB patients. Survey instruments were used to collect data from TB 
and LTBI patients, respectively. Survey research can be defined as “collecting information 
form a sample of individuals through their responses to questions”.(141) Using surveys that 
embedded HRQoL measurement tools was considered suitable to analyze HRQoL in light of 
the different variables of interest. This methodology follows the quantitative approach as 
outcomes were measured and analyzed quantitatively using statistical methods. However, as 
one of the objectives was to understand the factors influencing the experiences and HRQoL 
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of LTBI patients, qualitative interviews were conducted with a subset of these patients and 
analyzed in an integrated way with the quantitative data, which led to a mixed-method 
approach for study III (142), while study IV was solely quantitative. Another difference 
between the two studies is the design, as data from LTBI patients was collected at one point 
in time while for the TB patients a cohort study design was used with a follow-up assessment 
of HRQOL after 6 or 12 months depending on the treatment period. (143,144) Finally, the TB 
cohort was compared to the LTBI cohort which was considered a suitable comparison due to 
the similarity of socio-economic characteristics. The LTBI cohort was compared to a 
reference group consisted of the general population of Stockholm. Data about the general 
population of Stockholm was obtained through a regional survey by the county council 
“Stockholm hälsa 2014”(145) and was judged as the most up-to-date suitable local data 
source. 
Survey development  
A survey was developed and tested which included questions about basic socio-demographic 
characteristics, previous medical history (including TB history), diagnosis, treatment and side 
effects in addition to two validated instruments: the EQ-5D-3L instrument to assess HRQoL 
and the Refugee health screening-15 (RHS-15) instrument to screen for mental health issues 
among people with a migration background (146). The survey was available in the languages 
most commonly spoken by TB patients in Stockholm: French, English, Swedish, Arabic, 
Dari, Tigrinya, Somali, Mongolian. The qualitative interviews conducted for the mixed 
methods study were facilitated by an interview guide that was developed, tested and then re-
adjusted after the first few interviews to include topics of interest that patients touched upon 
and were missed in the preliminary guide. 
Inclusion and exclusion criteria  
To be included in the Survey, patients had to fulfill the following inclusion criteria: 
1) Age: 16 years old and older  
2) Medical diagnosis: TB or LTBI at the Infectious Disease or Paediatric clinics in 
Karolinska University Hospital, Sweden.  
3) Language skills: fluent in French, English Swedish, Arabic, Dari, Tigrinya, Somali or 
Mongolian. 
LTBI Patients with disabling medical conditions (HIV, organ transplant, dialysis, systemic 
rheumatic disease, ect) that were indications for LTBI screening other than country of origin 
were excluded.  
Data collection  
Patients were identified through electronic patient records at the hospital and recruited 
consecutively between September 2017 and June 2018. Consecutive sampling was 
considered a suitable equivalent to probability sampling technique for this study and all 
patients that met the inclusion criteria during the study period were invited to participate in 
the survey.(147) For the LTBI group data was collected at one time point, either at the 
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beginning of the treatment, during or at the end. For the TB group, data was collected at 2 
point in time; at the beginning of the treatment (first 2 weeks) and at the end (6 or 12 
months). 
A subset of LTBI patients who participated in the survey were asked to participate in a 
qualitative interview which took place immediately after the survey was filled based on their 
socio-demographic characteristics. Thus, a parallel convergent design was used, which allows 
the examination of qualitative and quantitative data in a concurrent fashion. The advantage of 
such design is reduced time of research and decreased risk of non-participation, which could 
be suspected in this patient group if a sequential design was used instead (eg. interviews 
taking place during a follow up visit). (148,149) Interviews were conducted until data 
saturation was reached. 
Sample size  
Sample size calculations were based on a 5 % significance level and 80% power. A 9% 
difference in the HRQoL of LTBI patients compared to a control group ( general population 
of Stockholm) was deemed suitable from the literature (136) leading to a required sample size 
of 52 LTBI patients. For the TB cohort, it was assumed that the HRQoL would increase by 
15 % by the end of the treatment and therefore 36 TB patients were required to detect this 
difference. 
Data analysis  
Data from the surveys were entered manually in Excel. The results of the 5 EQ-5D domains 
were dichotomized into no problem or problem (merging some and severe problems). In 
addition, these scores were used to generate the utility scores. Therefore, HRQoL data were 
presented as following:  a) counts (%) of patients with problems in each domain b), 
mean/median EQ-5D Visual Analogue Scale (VAS), c) mean/median of the utility scores. 
There were 3 different ways to compare the EQ-5D scores between 3 different populations: 
1) Comparing HRQoL at the start and end of treatment among TB patients 
2) Comparing HRQoL between LTBI patients and TB patients at start of treatment 
3) Comparing HRQoL  between LTBI patients and the general population of Stockholm  
The utility scores were obtained by using a HRQoL value sets. The Swedish experience-
based value set for EQ-5D was used in study III, while the UK hypothetical value set was 
used in study IV concerning TB patients.  
For the RHS-15 instrument, data were dichotomized into positive or negative as per 
guidelines of the instrument (146) and results were presented in term of counts (%) of 
patients who screened positive for mental health concerns. 
Data analysis for the LTBI patients included both qualitative and quantitative data therefore a 
mixed-method integration framework was used based on the conceptualization of HRQoL 
dimensions by Cherepenov et al. (150) which determines three main dimensions for HRQoL: 
physical, psychosocial and pain. 
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The qualitative interviews were transcribed verbatim in English and read thoroughly by 2 
researchers that coded the transcripts manually and then classified the codes under emerging 
categories that were linked to one of the 3 dimensions of HRQoL by Cherepenov et al. The 
quantitative data was also classified within this framework with the mobility, self-care and 
usual activity domains of EQ-5D corresponding to the physical dimension of HRQoL; 
pain/discomfort corresponds to pain, anxiety/depression along with the RHS-15 score 
correspond to the psychosocial dimension (illustrated in figure 7). Within each dimension, the 
qualitative and quantitative data were compared and contrasted and results were shown in a 
mixed-method meta-inferences indicating if the data reinforce and reassure each other 
(“confirmation”), contradict and negate each other (“discordance”) or if one data set explain 
and expand the understanding of the other (“expansion”)(149,151) . 
Figure 8 Matching the survey items to the main dimensions of HRQoL 
 
3.1.3 Cost-effectiveness analysis 
Literature review (study I) 
A review of the literature was conducted project to assess the methodology of LTBI CEA and 
develop a framework for the CEA to be used in this project. Three electronic databases 
(Cochrane Library, Medline and EMBASE) were searched for relevant studies in the filed 
with no limitation in term of language or time. In addition, reference lists of other systematic 
reviews were manually searched to make sure not to miss any potential study.  
Analysis 
Relevance of the studies was assessed based on inclusion and exclusion criteria that are 
summarized in table 3, these criteria were used by the first 2 authors of the paper in order to 
review titles/abstracts first and then the full text. Exclusion of studies was decided on and 
discussed with the senior author of the paper while documenting the reason of exclusion at 
different stages. The quality assessment of the studies was done using the Drummond 
checklist for economic evaluation of health programs, 2nd edition (110).  
Data from the included studies were extracted into four main data extraction sheets: 1) 
general economic model characteristics 2) disease and interventions characteristics 3) 
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program performance 4) target population characteristics. It is to note that meta-analysis of 
the data extracted was beyond the aim and scope of this review and therefore not performed. 
Results from the studies were analyzed and the main input parameters affecting the models’ 
outcomes were summarized in a framework along with the preferred characteristic of the 
economic models depending on the economic analysis perspective. This framework was 
largely built based on the Drummond checklist(110), a well-known standard checklist in 
health economics, while adding some specific aspects for LTBI screening. 
     Table 3 Inclusion and exclusion criteria for studies in the literature review of LTBI screening 
 
Markov modelling (study IV) 
Based on the framework generated through the literature review, a Markov model assessing 
the CEA of LTBI screening was developed in Excel comparing the current LTBI migrant 
screening strategy to a hypothetical scenario of no systematic LTBI screening/treatment. A 
societal perspective with a 50-year time horizon was chosen for the analysis with 2 main 
outcomes: HRQoL and averted TB cases. Therefore, ICER results were presented in term of 
marginal cost in Swedish krona (SEK) per QALY gained and marginal SEK per prevented 
case, respectively. When results are presented in term of SEK per prevented case, the analysis 
is considered a cost effectiveness analysis (CEA), while presenting the results in term of SEK 
per QALY falls under the cost utility analysis (CUA) umbrella.(110) Both costs and HRQoL 
data were discounted by 3% per annum according to the current Swedish recommendations. 
(117)    
The Markov model included 5 mutually exclusive health states as shown in figure 5, each 
individual move between these states according to his/her predicted health status at each 
cycle (which was set to 6 months): 
1) ”Healthy” : a person with no TB and no LTBI diagnosis 
2) ”LTBI state” : a person with undiagnosed LTBI or diagnosed but untreated or 
unsuccessfully treated LTBI 
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3) ”Treated LTBI state” : a person successfully treated LTBI 
4) ”TB state” : a person with active TB disease  
5) ”Dead state”: death 
To simplify the model and avoid having additional health states depending on the 
sensitivity/resistance of the bacterium, the TB state was averaged to include sensitive TB 
(87%), mono-resistant TB (10%) and MDR-TB (3%) to reflect the epidemiological situation 
in this cohort.  
Moving between the health states was determined by the time of the cycle (as the reactivation 
rate is higher in the first 2 years) and epidemiological probabilities which itself depends on 
the age of the individual. Therefore, it was decided to run the model for 5 different age 
groups (1-12; 13-18;19-34;35-54; and 55+). 
Data used in the economic modelling 
The LTBI cascade of care data was based on empirical data from a cohort of all migrants 
attending HE in Stockholm between January 1st 2015 and December 31st 2018. The cohort 
consisted of 5470 screened individuals. Data about their screening results, rate of referral to 
specialists and rate of treatment initiation and completion were extracted from electronic 
primary (HE and screening results) and specialist (evaluation of LTBI, treatment initiation 
and treatment completion) medical records linkable through personal identifiers to each other 
and to a registry of asylum seekers eligible for HE (demographic information, including 
country of origin), which was based on data from the Swedish Migration Agency. This 
record-linkage cohort study (84) is in the list of articles related to this thesis co-authored by 
the PhD candidate.  
Aligned with the societal perspective choice, different direct and indirect costs were included 
in the analysis, which were mainly derived from local databases, regional references and 
discussions with the Public Health Agency of Sweden. Direct medical costs included costs of 
the screening as well as treatment when initiated. Direct non-medical costs included cost of 
translators and transportation while the indirect costs were quantified in term of productivity 
loss. 
A conservative assumption was made to calculate the productivity loss based on the lowest 
10th percentile monthly salary in 2016, which was 22 000 SEK, plus 31% social fees paid by 
employer to the state.(152,153) Therefore, the total monthly productivity loss was 28 912 
SEK, divided into 21 workings days with 8 working hours/day which leads to a cost of 172 
SEK/hour. This cost has been added to all ages, as for children it was assumed that one adult 
will miss work to assist the child. The reason behind using the lowest 10th percentile salary is 
the difficulty for asylum seekers to get into the job market and therefore a conservative 
assumption would decrease the risk of any overestimation of the cost effectiveness of the 
screening program, since most of the productivity loss would be related to active TB.   
Despite a lack of clear guidelines of cost effectiveness threshold in Sweden, the National 
board of Health and Welfare usually consider an intervention to be very cost effective when 
the ICER is below 100 000 SEK/QALY, cost effective when the ICER is below 500 000, 
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moderately cost effective when the ICER is between 500 000 and 1000 000 SEK/QALY and 
not cost effective above 1 000 000 SEK/QALY.(41) 
 
3.2 ETHICS 
The cost effectiveness analysis part of the thesis did not need any ethical permit as it did not 
involve collecting information from individuals. For study II,3 and 4, which involved 
conducting interviews/surveys, an ethical permit was needed. The qualitative study II was 
granted an ethical approval by the regional Ethical Board in Stockholm county (reference 
Number: 2016/1648-32). Another permit was approved by the same board to conduct study 
III and 4 (reference Number: 2017/1595/31). As mentioned in these approvals, the major 
ethical concerns are related to the integrity of asylum seekers and TB/LTBI patients. 
Diagnosis can be linked to stigma and fear. Therefore, interviews can raise feelings of 
discomfort if not conducted in a careful manner. Asylum seekers might fear that their answers 
will affect their asylum process due to the suspicion that researchers work closely with the 
migration office, therefore the credibility and neutrality of the researchers is another major 
ethical challenge that need to be clarified and addressed before conducting any study. Finally, 
participants might fear that any statement or information they give will be linked in the 
future, and the anonymity topic should be addressed while conducting this research. 
For all studies, informed consent was obtained from respondents after introducing the 
purpose of the study and taking their approval for participation. The respondents were also 
informed orally and through the informed consent forms about their right not to answer 
questions and to terminate the participation without giving an explanation at any time. 
Finally, the respondents were informed about the confidentiality of the information and that 
all data will be analyzed anonymously. For study II, asylum seekers were informed verbally 
and through the written informed consent that the research is done with no connection to the 
migration office and the information shall not be shared with any authorities rather it is 






4.1 EXPERIENCES OF HEALTH EXAMINATION (STUDY II) 
Eighteen participants were interviewed to share their experiences of health examinations in 
Stockholm. Most of the participants (13) were men and the age range varied between 18 and 
48. Sixteen underwent the health examination while the other two had been invited but not 
participated at the time of the interview. The results of the study are summarized under the 
four areas of the AAAQ framework presented in figure 8. Overall, there was a perceived 
good availability, affordability and physical accessibility, especially facilitated by mobile 
clinics. Acceptability was high among the interviewees who felt respected and trusted the 
healthcare system.  
Concerns were raised about the delay in performing the examination which has implications 
on controlling infectious diseases as expressed by the interviewees. They also expressed the 
need for more information about the purpose and structure of the examination, as well as 
information about the Swedish healthcare system and their rights as refugees and asylum 
seekers to seek healthcare. Concerns were raised about the health examination in terms of its 
scope as interviewees did not experience the service as individual-centered, rather as a very 
generic evaluation for everyone regardless of their actual needs or health status. In addition, 
the examination was perceived to focus mostly on infectious disease control and not covering 
enough other important aspects for the interviewees, such as mental health and dental care. 
Interviewees questioned the value of the examination and screening for diseases while not 
offering effective treatment for all of them, mainly due to legal status and the restrictive rights 
asylum seekers are entitled for. 
 





4.2 HRQOL RESULTS (STUDY III AND IV) 
As shown in table 4, patients reported problems on two domains mainly: pain/discomfort and 
anxiety/depression. The highest percentages of reported problems were observed among TB 
patients at the beginning of the treatment followed by TB patients at the end of the treatment. 
In addition, 38% of LTBI patients scored positive on RHS-15. 
Table 4  EQ-5D results for each domain, utility score and VAS score for LTBI and TB patients 
 
 
The HRQoL of TB patients at the beginning of treatment phase was quantified as 0,72. This 
value increased to 0,84 by the end of the treatment, an increase that was statistically 
significant. The HRQoL of LTBI patients was reported as 0,84 which was similar to the 
HRQoL of the general Stockholm population. The same trend of changes was observed when 
analyzing the VAS score means and medians. The results show an increase of the VAS score 
through completion of TB treatment. 
Among the 47% of TB patients who experienced ADRs, the most common ones were nausea, 
rash and body pain, reported by 25%, 15% and 10%, respectively. 41% of LTBI patients 
reported ADRs; Nausea was reported by 18% while 11% reported dizziness. In addition, 
LTBI patients experienced fear and worry created through the LTBI diagnosis, which could 
be misunderstood as active TB and therefore concerns were raised about the fatality of the 
disease, its contagiousness and future uncertainties. This can explain the findings that anxiety 
depression was reported as a problem in the EQ-5D domain by 27.8% of LTBI patients while 
38% screened positive for some mental health concerns using RHS-15. Other factors that 
were identified through the quantitative research and can explain the deterioration of the 
mental health among patients include: unclarity about LTBI diagnosis, future uncertainties 
and the fear of infecting other family members. Table 5 summarizes the mixed-methods 




Table 5 Joint display of quantitative, qualitative and mixed methods inference results 
I go to school as usual, there are no changes, life is the 
same as before. (M, 38)
It goes ok with the treatment, I was a little tired in the 
beginning with some taste change in the mouth  but  I 
have to accept and solve the small side effects… I 
outweighed the benefit and the side effects. (F, 23)
Manageable physical side effects 
my wife and I have problems with stomach pain as we 
take it in the morning we feel some pain that 
decreases during the day. (M, 31)
I was scared and I said to myself I cannot even take the 
metro because I might infect others. (M,55)
Fear of being contagious
I have a baby that I was breastfeeding but after I got 
diagnosed I stopped breastfeeding him as I should 
not… I do not want to transmit the disease to him. 
(F,34)
I googled a lot about tuberculosis, I was afraid that I 
might die because of it or to find out that it is a 
dangerous disease. . (F, 25)
I was thinking so much and I was scared when I found 
out about TB , it is not good and who infected me? I 
just think a lot when I try to sleep I cannot sleep (F ,40)
Future uncertainties 
I think about the future, when I get older what if 
tuberculosis comes back and gets active then… (F,40)
I feel pain in my stomach after I started the treatment. 
I had stomach pain before but with the tablets it came 
back. (M, 32)
Ambiguous threat 
% scoring problems (95% CI) 
Quantitative findings
Confirmation             
patients ability for 
physical movement and 
functional activities was 
not compromised by the 






 Mobility : 7.4 % (2.4;12.4)
 Daily routines maintained
The medication doesn’t  interfere with anything in my 




I was very happy to start the treatment… it is very easy 
and I do not experience any side effects. (F, 27)
 Usual activities: 7.4 % (2.4;12.4)
Psychosocial
Expansion              
Patients' mental health  
was compromised due to 
unclarity about the 
disease itself, the future 
and the fear of infecting 
others
Experienced  pain
Pain Pain/Discomfort: 24.1 % (15.8;32.2)
The midwife gave me information about what I should 
get but I searched myself a lot of information. I felt a 
little worried that I might infect my children even 
though I see that I did not infect them but still I am 
worried anyway. (F,23)
Even now and after finishing the treatment we will 
still be worried about this disease, will we heal or will 
it activate to another disease, I don’t know.  (M, 31)
Expansion                      
pain and discomfort 
reported might  be 
attributed to 
Gastrointestinal side 
effects of the medication 
positive RHS-15 : 38% (28;47)
Anxiety/Depression : 27.8% (19.9;36.3) 




4.3 ECONOMIC ANALYSIS (STUDY I AND V) 
The literature review included 10 studies from 4 different low-incidence countries (Canada, 
USA, UK and Norway). The economic modelling was performed through a transmission 
model in one study while the rest used a Markov model (with or without a decision tree) to 
estimate the future costs and effects of LTBI screening. The screening process varied among 
settings in terms of target groups, procedures, screening tests and treatment eligibility, which 
made it hard to compare between the studies. Another major difference detected was the type 
of costs included which was determined by the economic perspective of the study. Five 
studies adopted a healthcare perspective including all costs paid by the healthcare system, 
while three studies included costs paid by governmental agencies (governmental perspective), 
one study included both governmental costs as well as out of pocket payments. Finally, one 
study adopted a societal perspective and included all types of costs incurred, including 
productivity loss. 
The review showed a wide variation in terms of epidemiological, test accuracy, efficacy and 
ADR assumptions. Assumed TPT efficacy ranged between 65% till 100%. The program 
performance parameters in term of screening coverage, treatment initiation and completion 
rates also varied, and these parameters were main drivers of variation in cost-effectiveness 
results, as demonstrated by sensitivity analyses. Only 2 studies reported the proportion of 
treatment being offered when the person is eligible, however studies usually specified the 
treatment initiation and completion rates with the majority of studies using empirical data 
while 3 studies used assumptions. Finally, reactivation rates and LTBI diagnostic tests 
characteristics were also important determinants of cost-effectiveness as shown in the 
sensitivity analysis, however these parameters where quantified differently across studies. In 
some studies, the reactivation rates were stratified according to time since infection, HIV 
status or the assessment of reactivation risk.  
Based on the literature review findings a framework to help standardizing approaches and 
methodology used for economic modeling of LTBI screening among immigrant in low 
incidence settings was developed. This framework was influenced by the Drummond 
checklist (110) while tailoring it to fit LTBI screening in immigrants. This framework (figure 
8) was used to develop the Markov model assessing LTBI screening in different cohorts 
compared to no screening in place in Stockholm in study V. 
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Figure 10  Framework for economic modelling of LTBI screening in migrants to low TB incidence 
countries.  
 
TB=tuberculosis; LTBI= latent tuberculosis infection; MDR-TB= multidrug resistant TB; CEA= cost 
effectiveness analysis; QALY= Quality adjusted life years; CUA= cost utility analysis; CBA= cost benefit 
analysis. 
 
The economic model predicted that the present screening approach conducted during four 
years (2015-2018) would prevent 25 cases in the study cohort over a 50-year time horizon 
compared to no screening. The majority of cases (64%) would be prevented among 
adolescents (age 13-19). Table 6 presents the results of CEA and CUA by age group and 
country TB incidence categories. The CUA showed that the ICER is lowest among the age 
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group 13-19 at to 303 881 SEK/QALY. This was the only ICER below the 500 000 
SEK/QALY threshold. The ICERs of screening the age groups 0-12 and 20-34 were between 
500 000 and 1 000 000 SEK/QALY while screening older groups generated ICERs > 1 000 
000 SEK/QALY. The same trend was observed with the CEA.  
Within each age category, the ICER generally got lower as the country TB incidence got 
higher. For example, in the age group 20-34 the ICER was around 500 000 SEK/QALY for 
immigrants from highest-incidence countries (> 300/ 100 000), and gradually increased to 1 
431 023 SEK/QALY in immigrants from the lowest-incidence countries (<50/100 000) (table 
6). 
As predicted through the literature review, the cascade of care parameters largely influenced 
the economic analysis results. Our analysis of the screening cascade (84) found that the rate 
of referral to TB clinic following a positive IGRA was around 70% for groups younger than 
20 years old which drops drastically to less than 30% for the older groups. This affected the 
rates of initiating treatment among IGRA positive patients with the highest rates among 
younger patients (55% for age group 0-12, 66% age group 13-19) while it dropped to 17 % in 
the age group 20-34 and to around 4% for older cohorts. Rates of finishing initiated treatment 
were high among all groups. 
In a scenario analysis for the age group 20-34, empirical cascade parameters (31% visiting 
TB clinic, 17% of those starting treatment and 83% of them completing treatment), were 
changed to match the empirically observed data for the age group 13-19 (70% visiting TB 
clinic, 65% of those starting treatment and 94% of them completing treatment), the ICERs 
decrease to 274 626 SEK/QALY, and 208 812 SEK/ prevented case, hence increasing the 










Table 6 Results of Cost effectiveness analysis by age groups and country and by TB incidence in 













5.1 GENERAL DISCUSSION 
Health examination, an entry point for TB control and health needs assessment 
Health examination is the main entry point in Sweden for systematic TB and LTBI screening 
of asylum seekers and refugees. Therefore, understanding the opportunities and obstacles 
around this examination is one of the first key steps for optimal and cost-effective screening 
in this vulnerable group. The results of this thesis are consistent with the available literature 
about the experiences of asylum seekers and refugees with health examinations in Sweden. 
Study II along with other research suggest that asylum seekers and refugees in general have a 
positive attitude towards the health examination and perceive it as an opportunity to improve 
their health status and learn about the health system. However, several challenges have been 
repetitively identified in different studies, mainly including: unclarity and communication 
issues, focus on infectious disease control only rather than all aspects of health, and lack of a 
person-centered approach. (92,94,95,154) 
Unclarity due to miscommunication or lack of information is a main challenge that can 
compromise the value of the health examination. A survey showed that 36% of participants 
perceived the communication during the health examination as poor while 55 % report that 
they received little information about Swedish healthcare through the examination. (95)This 
unclarity, communication challenges and limited accessibility to information can trigger 
feelings of insecurity and compromise the perceived value of the examination. (91,92,94,154) 
Aligned with the findings of this thesis, the communication in HE has been reported also 
elsewhere to be perceived as a one-way phenomenon rather than an actual dialogue with a 
healthcare professional. In other words, some participants perceived the goal of the service as 
the health care provider gathering information from them rather than giving them the 
information they need, which is an aspect of the HE that should be improved in the 
future.(94) 
Information need to be given clearly to the participants about the purpose of HE, about which 
diseases they may get tested for, as well as about their rights and the free-of-charge treatment 
they may receive for certain infectious diseases.  
The request for more holistic and comprehensive HE should not be interpreted as critique by 
participants that too much infectious disease screening is done. On the contrary, they seem to 
take for granted that this should be included. The concern about the delay of the examination 
should be tackled as it could have implications for both infectious disease control and the 
perceived value and willingness to participate in HE. It could lead to fear of disease 
transmission, both from the participant him or herself to others, as well as from others to the 
participant, which could indirectly contribute to worry and stress. However, it is worth 
mentioning that the long delays were mainly observed after the big influx of refugees in 
2015-2016. As these numbers substantially decreased the following years, the delays were 
shortened.   
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One study showed that 2 out of 3 individuals perceived the HE as a pure communicable 
disease measure rather than an assessment of the actual health needs, with 55 % of the 
respondents perceiving that their actual needs were over-looked especially the mental illness 
aspect.(92)In another study conducted in four different Swedish regions, unmet expectations 
and health needs were highlighted by interviewees especially in term of mental health needs. 
(154) As a result, participants can have a feeling of disappointment as the service does not 
fulfil the image of an adequate examination from their perspective, if not person-centered, 
covering health in a holistic manner and providing immediate help except for urgent care. 
(94) In addition, screening and overlooking some health needs, like asking about mental 
health without offering any support or possible referral, raises an ethical dilemma and might 
have a negative impact in practice. In the “The ethics of screening: Is 'screeningitis' an 
incurable disease?” authors discussed the ethical, practical and economic dilemmas of 
offering screening and treatment to a certain population. The article emphasizes the need to 
offer treatment following any screening otherwise withholding any intervention can cause 
more harm than not performing the screening. (155) 
A main argument against granting universal health coverage for this vulnerable group is the 
expected high costs. However, this is not backed up by any evidence in the literature. On the 
opposite, studies in different European settings showed that more inclusive healthcare 
packages for asylum seekers can decrease the direct and indirect costs on the long run, and 
healthcare savings could be achieved through preventing progression to serious and chronic 
diseases. In addition, these migrants will contribute to the economies of the host country 
therefore reducing productivity loss is a strong argument for less restrictive healthcare 
policies. (156–159) 
The use of mobile clinic for HE was seen as a favorable approach in this thesis, as well as in 
other studies (160,161). It may be an effective way to remove geographic and social barriers 
and therefore potentially increase participation and decrease any delay, especially in case of 
an influx of high number of asylum seekers in a short period of time. 
In summary, we found that the interviewed asylum seekers and refugees overall had a 
positive attitude towards HE, including TB and LTBI screening, but also saw room for 
improvements.  
 
Mental and physical components of HRQoL in persons with TB or LTBI 
Mental health 
Mental health among asylum seekers was not a main focus of this thesis but nevertheless 
mental health concerns have been a recurrent theme, whether linked to asylum seekers’ 
general health and related HE expectations or an element of HRQoL linked to LTBI 
screening and treatment or TB disease.  
As discussed above, asylum seekers perceived mental health as one of their main needs that 
should not be overlooked by healthcare and the HE. These qualitative findings are supported 
by the high prevalence of mental health concerns among asylum seekers and refugees in 
Sweden, for example in term of high prevalence of depression, anxiety and PTSD shown by 
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several studies (162,163). Those findings are in line with the high RHS-15 scores found in 
study III, as well as the high proportion of patients scoring problems on the EQ-5D mental 
health domain. Many factors contribute to the exacerbation of mental health concerns. Some 
factors are related to the pre-migration phase such as trauma and exposure to danger and war. 
However, many factors are related to the post-migration phase in the host country, including 
uncertainties and worries related to legal questions, unclarity about health care and other 
welfare systems in the host country and perceived inability to seek and receive the healthcare 
they need, as shown in this thesis as well as in the literature. (164,165)   
Concerns about mental health are common in this vulnerable group regardless of the TB 
status. However, being diagnosed with LTBI or TB can add another layer of complexity. Fear 
of reactivation of LTBI can be linked to future uncertainties and compromised mental health 
as shown in this thesis. The knowledge of a serious and deadly disease being dormant in their 
bodies can trigger the sense of fear among patients. (132)In addition, TB can be a 
stigmatizing disease, perhaps more so in their country of origin. Therefore, patients may fear 
discussing LTBI diagnosis with their family or friends. Stigma is related to the perceived risk 
of transmission to other members, as well as its association with HIV, low social class and 
poverty, even in low-incidence countries, which can impact mental health, treatment 
adherence and clinical outcomes. (166,167) 
This stigma is rooted with many misconceptions about TB and LTBI. A study conducted 
among immigrants in the north of Sweden showed a poor knowledge about TB disease and 
LTBI. Participants had a negative attitude toward TB along with many misconceptions. Poor 
health literacy can be linked to inaccessibility of information, a challenge that can be tackled 
through including more attention to TB education as part of screening programs in Sweden, 
at least within the high-risk groups to address misconception and increase awareness about 
prevention. (168) Another important pathway could be through programmatic tackling of 
mental health as part of TB and LTBI management. Integrating mental health with TB 
control might be of a good value in a setting such as Sweden where the majority of the LTBI 
and TB cases are among immigrants who might have limited knowledge about navigating 
and using healthcare services. (169) 
Physical health 
Patients on anti-TB medicines, for TB or LTBI, can experience ADR such as skin reactions, 
gastrointestinal side effects and hepatotoxicity, which is a severe side effect that can lead to 
treatment discontinuation. Therefore, it is recommended to monitor liver enzymes in patients 
on anti-TB drugs, especially for persons 35 years of age and older according to the WHO 
recommendations. (24,49,50) None of the LTBI or TB patients enrolled in study III and 4 
experienced hepatotoxicity. However, the sample was small. Patients instead reported milder 
side effects such as nausea and pain, which can explain the high percentage of reported 
problems on the pain/discomfort dimension of EQ-5D in both the TB and LTBI groups, 
although mainly in the TB group.   
In term of the physical health dimensions of EQ-5D, very few LTBI patients scored problem 
on mobility, self-care and usual activities, while a higher percentage of TB patients scored 
problems on mobility and usual activities dimensions even at the end of the treatment, which 
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is in line with the fact that TB disease can be severe, lead to a variety of symptoms, disability  
and discomfort, as well requiring a treatment regimen with several medicines, each which can 
give several types of ADR.  
 
HRQoL scores 
To our knowledge study III and 4 are among the first studies that have quantified the HRQoL 
of TB and LTBI patients and generated utility scores in a European setting where the majority 
of patients belong to migrants’ population. A similar study, which did not focus on migrants 
only, has been conducted in the UK using EQ-5D and SF-36 and it showed similar results in 
term of the high percentage of TB patients scoring problems on pain/discomfort and 
anxiety/depression dimensions of EQ-5D at diagnosis as well as at 2-months follow up. (170) 
However, that study did not generate any utility scores. Our results are also in line with the 
evidence from HRQoL studies conducted in the USA and Canada which showed a 
significantly lower HRQoL among TB patients compared to LTBI patients and the general 
population in these settings both during and after treatment. (136,171)However, this thesis as 
well as the available literature emphasize that in a group of predominantly newly arrived 
migrants, mental health concerns may also be unrelated to TB and reflect the general QoL 
issues of migrants like the legal concerns. 
The mental health concerns discussed above were not reflected in the utility scores values 
derived from the LTBI group, as the scores were relatively high and similar to the general 
population of Stockholm. This can be due to the heavy preponderance of physical items in 
EQ-5D and its questionable sensitivity to mental health concerns which has been debated in 
the literature. Some criticize the large focus of EQ-5D on the physical dimension of health 
compared to the psychosocial aspects. (172,173)In addition, EQ-5D-3L has been criticized 
for its ceiling effect, a phenomena that occurs when most of respondents declare no problems 
in a certain dimension, especially compared to SF-12, which was also able to better detect 
changes in symptom severity.(174,175)In addition, EQ-5D-5L has shown less ceiling effect 
and better properties a better discriminative power, hence better at detecting changes in 
scoring within each dimensions, compared to E1-5D-3L, making it more favorable. (176–
180) 
A head-to-head comparison of the 3- and 5-level version of EQ-5D shows differences 
between the two instruments. The highest weight for the EQ-5D-5L was for 
anxiety/depression while it was mobility for the 3L version, emphasizing again the physical 
health focus of the EQ-5D-3L instrument. (176) The increased sensitivity of the 5 levels 
version also favors QALY gains even if the changes in utility are smaller, and therefore the 
3L and 5L lead to different utility scores which impact cost-utility outcomes in different 
ways. (181,182) With the current evidence leaning toward the use of the EQ-5D-5L, further 
research might be needed in the future about the use of EQ-5D-5L among TB and LTBI 
patients. For this thesis the EQ-5D-3L version was favored due to the availability of the 
instrument in the languages of the asylum seekers in Stockholm, but when there is no 
language barrier EQ-5D-5L might lead to better understanding of the HRQoL. 
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As expected, the mean utility score of TB patients was significantly lower compared to the 
LTBI group, although it improved by the end of the treatment. This is in line with the 
findings of the few HRQoL of TB patients in low-incidence countries. None of these studies 
generated utility scores through EQ-5D and therefore straight forward comparisons cannot be 
made. However, one study in Thailand used EQ-5D and showed a median EQ-5D score of 
0,69 which increased to 0,88 after successfully completing the treatment, similar to our 
results. (183) 
Finally, an LTBI diagnosis might trigger feelings of fear, insecurity and anxiety as discussed 
before, hence screening without the possibility of providing preventive treatment can cause 
more harm than not screening and it can be seen as morally wrong. In addition, this thesis 
showed that screening in many age groups was very costly for healthcare and society, 
especially in the older groups that have very restrictive access to preventive treatment. 
Therefore, effectiveness and cost-effectiveness of the LTBI screening program assessed 
through this thesis is questionable, which will be discussed in the next section. 
 
Cost effectiveness of LTBI screening 
Based on the cost effectiveness thresholds used in this thesis, our results suggest that LTBI 
screening in Stockholm is cost effective only for some age groups, moderately cost effective 
for others while it is very costly and not cost effective for others. Apart from age, the results 
were influenced by TB incidence in the country of origin, as well as by factors related to 
screening and treatment policy. Patient adherence played a minor role in determining cost-
effectiveness. 
The findings of this thesis showed that LTBI screening was cost effective in the age group 
13-19 and therefore it should be continued to be recommended for them, from a resource 
allocation perspective. Within this age group, the cascade of care indicators show a high 
referral rate to TB clinics and high treatment initiation and completion rate with low 
dropouts. Despite the high adherence to treatment in the youngest group (age 0-12), the ICER 
was higher and the strategy was not as cost effective as for the age group 13-19 years and this 
was mainly due to the fact that only a small percentage of children are infected and thus 
diagnosed with LTBI.(84) However, on the individual level LTBI treatment in young 
children is often even more valuable than for older individuals due to high risk of activation 
and severe consequences of TB disease. Despite being only moderately cost-effective, 
screening children aged 0-12 can still be a priority. 
For the age group 20 to 34, the ICER falls between 500 000 and 1 000 000 SEK/QALY and 
deemed as moderately cost effective. Although increasing prevalence of LTBI with age 
means increasing cost-effectiveness with age, this is counteracted by the fact that a low 
percentage of these patients are actually offered preventive treatment in Stockholm. Hence, 
there were screening costs without any clear corresponding utility for the vast majority of 
persons over the age of 20 years.   
The conservative strategy of referring and treating IGRA+ patients has been questioned, 
especially when comparing to other regions of Sweden where treatment is often generally 
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offered for patients up to the age of 30 or 35 years, in line with the recommendations of the 
public health agency. (81,84) Our scenario analysis within the age group 20-34, using higher 
referral rate of IGRA positive patients and higher treatment initiation/completion rates that 
matched the rates observed for the 13-19 years cohort, showed an improved cost-
effectiveness that fell well below 500 000 SEK/QALY. Therefore, recommending screening 
for this age group makes sense if treatment is offered to all who are screened positive. The 
same conclusion was drawn from a study in Norway, a similar setting to Sweden. The cost-
effectiveness analysis of their LTBI screening emphasized the importance of increasing 
treatment initiation among patients up to the age of 35 years to make it cost effective. (184) 
For individuals aged 35 and above, LTBI screening was not cost-effective, leading to high 
ICERs and therefore it is not recommended. In line with our findings, the new guidelines of 
the public health agency of Sweden (from 2020) do not recommend IGRA testing among 
these individuals as only few would be eligible for treatment. As TPT has higher risk of 
hepatotoxicity in older persons, the risks might outweigh the benefits. (81) Hesitancy in 
prescribing preventive treatment for persons above the age of 35 means that it might be more 
effective to focus on screening for active TB only in this age group. This means discontinuing 
IGRA screening while replacing it with chest X-ray and perform IGRA only in case of a 
normal chest X-ray and in presence of additional risk factors for progression, as the public 
health agency now recommends. (81) This new recommendation by the Public health agency 
has not been evaluated for its effectiveness or cost effectiveness and further research is 
needed to have a firm conclusion on the yield and cost per detected case with X-ray 
screening, compared to for example only symptom screening. The number of persons 
detected with active TB in our screening cohort was only 12,(84) indicating that many 
persons would have to be screened for each active case to be detected.    
Another influential factor on the CEA results was the country of origin. As predicted from the 
literature review, the higher the incidence rate of the country of origin, the higher the cost 
effectiveness of LTBI screening. These findings are in line with the available evidence from 
other European countries such as Germany and the UK. (185,186) Moreover, a cost-
effectiveness study performed by the ECDC covering four countries (Spain, Netherlands, 
Portugal and Czech Republic) concluded that LTBI screening is cost effective when 
individuals from very high incidence countries are targeted. (54) The thresholds in these 
studies varied, however our findings showed that screening individuals from countries with a 
TB incidence higher than 200/100 000 is cost effective for all individuals younger than 35 
years old. Therefore, any recommendations and updated guidelines should take the country of 
origin into account combined with the age and the risk factors assessment. 
Comparing the cost effectiveness analysis results to other studies in other countries is 
challenging due to difference in modelling approaches and assumptions, as demonstrated by 
our literature review of methods used in economic evaluations of LTBI screening. 
Harmonizing the methods of LTBI screening evaluation is a challenge that should be 
addressed to facilitate cross-country comparisons and policy analyses in the future. The 
framework for economic modelling of LTBI screening developed as party of this thesis can 
serve as reference to reduce methodological differences and improve comparability.  
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Despite the methodological variations, some firm conclusions can be drawn about promising 
success factors for cost-effective screening that we have uncovered, which are partly at odds 
with previously published data. High attrition along the LTBI cascade of care was a limiting 
factor for the cost effectiveness of LTBI screening in several previous economic evaluations 
of LTBI screening, and much of the attrition has been assumed to be due to lack of patient 
adherence. This has led ECDC to recommend LTBI screening only when screening 
programmes can ensure a high screening uptake and treatment initiation. (54) Designing 
more effective and cost-effective screening entails addressing both patient and provider 
factors. In the cohort used for our analysis, 97% of patients who were recommended 
treatment started treatment and among those 91% completed the treatment (84).The high 
attrition in our data was mainly explained by health workers following the existing 
guidelines, most importantly the recommendation not to start people over the age of 20 years 
on treatment unless that had additional risk factors. The potential for further improvements in 
the care cascade, and thus of cost-effectiveness, seem largely to be in the hands of policy 
makers and clinicians. There are still some outstanding questions about the age threshold at 
which the value of providing TPT no longer outweighs the risks. Nevertheless, once there is 
agreement on which age groups to offer treatments for, our data suggest that patient 
adherence may not be not be a key challenge in Sweden, and also more generally that patient 
adherence should be possible to optimize in all countries where this type of screening is 
offered, given the right supportive health systems structures.    
 
5.2 METHODOLOGICAL CONSIDERATIONS 
Qualitative and Mixed-Methods designs  
Despite the added value of qualitative research in this thesis, many methodological challenges 
need to be highlighted. To assess the health examination, participants were recruited from 
four different settings.  However, selection bias may be an issue as the participants who 
volunteered may misrepresent or have less health needs than the general asylum seeker 
population in Stockholm. In addition, it was difficult to recruit asylum seekers who had not 
undergone a health examination in these settings, so no conclusions can be drawn about “no 
participation”. For the mixed-methods study, the subgroup that participated in the interviews 
are deemed to be representative of LTBI patients in Stockholm due to their socio-
demographic characteristic and the recruitment strategy based on the electronic medical 
records. A concurrent design was applied in this study. An alternative approach would have 
been to use a sequential design, meaning that the interviewees are chosen based on their EQ-
5D and RHS scores. The advantage of sequential design is that it would allow us to interview 
individuals with worse health status and to deepen the understanding of their needs, but this 
design can be challenging as it requires contacting some patients and booking an interview 
time which can be compromised by participant hesitancy and drop-outs. 
In addition, interviews were conducted in different languages and translators were used, so 
there is a possibility that information was lost during the process of translation. However, the 
main author spoke well in some of the languages and that gave some participants to speak in 
a language that feel comfortable with thus ensuring they express their experiences easily. 
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The generalizability of qualitative research findings is another challenge, and we 
acknowledge that our results may not be applicable for asylum seekers in other parts of 
Sweden. However, our results are in line with the available evidence from studies in other 
Swedish counties.  
 
HRQOL  
HRQoL of TB and LTBI patients can be measured by using different instruments. The choice 
of EQ-5D-3L for this study was mainly based on the availability of the instrument in the 
needed languages, However, as discussed above EQ-5D-5L could be a more suitable and 
sensible instrument, or alternatively SF-36. There is no gold standard for measuring HRQoL 
among TB patients and the available studies vary widely in the variety and analysis of results.  
For our analyses, the EQ-5D-3L responses were used to generate utility scores. The choice of 
value set is a challenge as the asylum seekers come from different countries and constitute a 
very heterogenous cohort from different countries. In study III, the LTBI cohort was 
compared to the general population of Stockholm. Using the Swedish experience-based value 
set was the ideal choice to use among the Stockholm cohort. Therefore, to allow comparison 
between the two groups, the same value set was used to generate the utility of score of LTBI 
patients. As a sensitivity analysis, the UK hypothetical value set was used and generated very 
similar results with the same median and 75th percentile, being 1, and a slightly higher 25th 
percentile (0,83 instead of 0,79).  
For the active TB cohort who are foreign-born, there was no reason to believe that the 
Swedish experience-based value set is an appropriate choice, so the UK hypothetical value 
set was used instead as it facilitates comparison with future studies. As a sensitivity analysis, 
the Swedish experienced-based value was used and generated a mean utility score of 0,77 at 
the beginning of the treatment which increased to 0,91 by the end of the treatment, a 
statistically significant difference with a p-value < 0,001. The higher values generated 
through the Swedish experienced based value set were expected as shown in a study 
comparing the two value sets.(187) Comparison with the LTBI cohort lead to a statistically 
significant difference regardless of the value set choice.  
 
Economic modelling  
Despite being based on a real-life cascade of care data, the economic analysis has many 
methodological limitations due to the simplification of the model and the assumptions used in 
terms of epidemiological parameters. 
The model developed through this thesis is a Markov model and therefore it is not a 
transmission model that can accommodate for transmission of infection among individuals.  
In addition, the model could have overestimated the cost effectiveness of LTBI screening 
through the following assumptions and simplifications: 1) not including the costs of potential 
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ADR and its impact on treatment adherence; 2) assuming a 100% sensitivity of IGRA which 
does not represent the real-life situation and; 3) assuming a 100% efficacy of TB treatment.  
To simplify the model, another assumption was made in terms of standardizing the 
reactivation rate of LTBI for all patients regardless of their age, risk factors and time since 
infections, even though these factors are shown to impact the risk of reactivation. We did not 
have data on time since infection or risk factor profile of the screened persons so could not 



























The results of this thesis can lead to some recommendations summarized below:  
 
 Health examinations are a suitable way to screen asylum seekers for infectious diseases, 
including TB and LTBI. However, they should be used as an opportunity to address the 
health needs of asylum seekers through a holistic approach that goes beyond infectious 
disease control. 
 
 Asylum seekers diagnosed with LTBI need better information in order to raise awareness 
about the disease and address misconceptions and stigma related to TB disease. Mental 
health care can be part of LTBI management if patients seem worried and if the diagnosis 
compromised their quality of life and well-being. 
 
 TB patients in Stockholm have a compromised HRQoL and a decrement of 0,28 was 
calculated through this thesis. This estimate can be used in other health economic models 
for similar epidemiological and demographic settings. However, future research using 
EQ-5D-5L or SF-36 might be valuable to validate or finetune the results of this work. 
 
 LTBI screening should only be performed when the individuals are eligible for TPT, 
otherwise screening is not cost-effective, and it can be unethical and even compromise 
mental health of asylum seekers by creating unnecessary worry and stigmatization. 
 
 LTBI screening followed by initiation of TPT in Stockholm is cost-effective and 
recommended for individuals under the age of 35. For older patients, the current LTBI 
screening strategy is not recommended. The alternative strategy of chest X-ray screening 
followed by IGRA screening is not evaluated and future research is needed to assess the 






LTBI screening among asylum seekers in Stockholm is cost-effective in adolescents, while it 
is moderately cost-effective in children under the age of 13 and in the age group 20 to 34. The 
moderate cost-effectiveness in the age group 20 to 34 is mainly due to the restrictive practices 
of offering treatment for persons over the age of 20 years. The cascade of care indicators 
affected the cost-effectiveness analysis results to a large extent, mainly in terms of the 
proportion being referred and offered treatment. Therefore, screening should only be 
recommended for asylum seekers who are potentially eligible for treatment. 
Our findings show that TB disease can affect the physical, psychological and social well-
being of asylum seekers substantially. Mental health concerns are prominent among LTBI 
patients who are asylum seekers or refugees, but this is probably more due to migration-
related factors than to LTBI. Nevertheless, there is a need for a holistic approach to TB and 
LTBI-care among this vulnerable group, including mental health support and improved 
systems for communicating information to address the concerns of patients, clarify the 
differences between TB and LTBI, and decrease the stigma around TB disease.  
Uncertainties, fears and misconceptions among asylum seekers are not limited to LTBI 
diagnosis and they should be addressed earlier during the health examinations regardless of 
the LTBI status. Health examination is acceptable, accessible and affordable according to 
asylum seekers. However, its quality and perceived value can be compromised if its focus is 
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